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CHAPTER I 
INTRODUCTION 
The hereditary porphyrias are a group.of relatively rare metabolic 
diseases involving defects at various sites in the heme biosynthesis 
pathway. In general, the porphyric diseases are characterized by the 
production of large amounts of porphyrins and/or porphyrin precursors 
and by clinical signs which range from photosensitivity and anemia to 
neurological disturbances (46). The porphyrias of man are grouped into 
two major categories based on the type of ti.ssue in which the metabolic 
defect is expressed; those in whic,h the defect is manifested in eryth-
roid tissue (erythropoietic.type) and those in which the defect is 
manifested in .. non,-erythrc:>id tissue (hepatic type). Sub·types within 
each of these categories are classified according to specific patterns 
of clinical signs and excretion patterns of porphyrins and porphyrin 
precursors (44). 
Diseases of porphyrin metabolism may also be induced by ~ertain 
drugs and chemicals.(124). Although studies of the acquired distur-
bances in porphyrin metabolism have aided in the clarification and 
1.mdtarstanding of defective porphyrin metabolism, the major impetus for 
investigations of both normal and abnormal porphyrin metabolis~ has been 
generated through interest in the hereditary porphyrias of man. 
1 
The classification of the hereditary porphyrias of man used in 
this thesis follows that suggested by Goldberg (44): 
I. Erythropoietic 
A. Congenital erythropoietic 
B. Erythropoietic protoporphyria 
II. Hepatic Porphyria 
A. Acute intermittent porphyria 
B. Porphyria variegata (mixed) porphyria 
C. Hereditary coproporphyria 




Hereditary porphyria among domestic animal species has been re-
ported in cattle (32), swine (68), and more recently in the domestic 
cat. (140). The condition in cattle and swine is classified as con-
genital erythropoietic porphyria, although certain features of the 
disease in these species are dissimilar to those which characterize 
congenital erythropoietic porphyria in man ~~. The disease in swine 
is inherited as an autosomal dominant trait and as an autosomal re-
cessive trait in cattle and man; Feline porphyria was first reported 
in 1964 in two littermate kittens (140). The kittens were observed to 
have brownish discoloration of the teeth which exhibited reddish 
fluorescence under ultraviolet light. Limited qualitative urine analy-
ses performed on one porphyric kitten indicated the presence of uro-
porphyrin, coproporphyria, and porphobilinogen. Signs of photosen-
sitivity were absent. 
A research colony of porphyric cats has been developed at Oklahoma 
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State University from progeny of the dam of the porphyric kittens de-
scribed in the original report. Genetic.studies in this colony indicate 
a Mendelian autosomal dominant mode of inher.itance for the porphyric ·· 
trait·(41). The porphyric cats exhibit many features in common with 
thos~ of congenital erythropoietic porphyria in other animals and man; 
however, certain features of feline porphyria overlap those of eryth-
ropoietic protoporphyr~a and the hepatic porphyrias of man (43). 
The present investigation was designed to more completely charac-
. terize the metabolic defect(s) involved in feline porphyria. More 
specifically, the studies were designed to provide further information 
regarding urinary·excretion patterns of porphyrins and porphyrin pre-
cursors,and erythrocyte porphyrins as well as to provide data regarding 
activity of specific enzymes more likely to be involved in defective 
heme biosynthesis in th.e porphyr:i.c cat. 
CHAPTER II 
REVIEW OF SELECTED LITERATURE 
Normal Heme Biosynthesis 
The metalloporphyrins, chlorophyll and heme, occupy a central posi-
tion in life processes. Chlorophyll performs a vital role in the photo-
synthetic process which is fundamental to the support of all forms of 
life. Heme performs a vital role as an integral, functional component 
of hemoglobin, myoglobin and hydroperoxidases, as well as certain of 
the enzymes involved in electron transport systems (46). 
The enzyme mediated steps leading to the formation of heme in micro-
organisms, plants and higher forms of life have been elucidated; how-
ever, the exact reaction mechanisms by which certain metalloporphyrin 
precursors are formed remains unclear. Heme and chlorophyll are de-
. 
rived from protoporphyrin IX which is formed by an identical biosynthe-
tic pathway in both plant and animal forms of life (Figure 1). Four 
isomer types of porphyrins are structurally possible but only types I 
and III are produced in biological systems but only the type III isomer 
can be utilized in the biosynthesis of heme. 
A large body of knowledge concerning both normal and abnormal heme 
biosynthesis has been gained by studies of diseases of porphyrin meta-
bolism. Fischer and co-workers (28,29,30,31), during the period of 
1915-1930, resolved the structure of heme by an extensive series of 
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Figure 1. The Bathway of Heme Biosynthesis and porphyrin Formation. 
5 
erythropoietic porphyria. Later investigations of defective porphyrin 
metabolism by numerous workers have aided in clarification of the 
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various steps in the heme biosynthesis pathway. St~dies involving 
chemically induced as well as hereditary1'porphyrias have provided in-
formation regarding possible control mechanisms regulating heme synthesis. 
Based on results of -these studies, a postulation of feedback repression 
of o-aminolevulenic acid synthetase in a manner similar to the mechanism 
proposed by Jacob and Monad (64) for regulation al .enzyme formation in 
microorganism was suggested as one means of controlling heme biosyn-
thesis (49). 
Biosynthesis of o-Aminolevulinic Acid 
The initial step in heme biosynthesis is the formation of o-
aminolevulinic acid (ALA) by condensation ef succinyl-CoA and glycine. 
Isotope labeling studies by Shemin and co-workers (110,133) demonstrated 
that the nitrogen atoms in protoporphyrin IX, as well as the methene 
bridge carbon atoms and four-of the eight alpha carbons, are derived 
from glycine. Shemin et al. (132) further demonstrated that the re-' 
maining carbon atoms in protoporphyrin are·derived from succinate. On 
the basis of this and other work, Shemin, Talmage, Kumar, and Kikuchi 
(78) concluded that succinyl CoA was the specific compound which con-
denses with gylcine to form ALA. Further studies using duck red cell 
hemolysates incubated with 14c ALA and 14c glycine demonstrated that ALA 
is an essential precursor of heme (134). 
The formation of ALA from glycine and succinyl CoA is catalyzed by 
the enzyme, ALA synthetase, which is located in the mitochondria of avian 
and mammalian cells (122,37). Pyridoxal phosphate is required as a co-
factor in the reaction. ALA synthesis does not occur in in vitro 
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systems centaining the partially purified enzyme preparation without the 
addition of pyridoxal phosphate (78,83). Evidence that this vitamin is 
required ..!!!. vivo is provided by the demonstration that pyridoxal phos-
phate deficient ducklings, pigs and man develop a hypochromic anemia 
which is corrected by administration of the vitamin (136,156,60). Ad-
ditionally, Schulman and Richert <i36) showed that pyridoxal phosphate 
deficient duck red cells synthesized heme at a reduced rate which was 
corrected by adding the vitamin to the system. 
The conversion of glycine and succinyl CoA to ALA is considered to 
be the rate limiting step in the heme biosynthesis pathway (49,52). 
Three possible mechanisms by which heme production could be regulated at 
this, step in the pathway are: 1) by control of the rate of enzyme de-
gradation, 2) by negative feedback inhibition of ALA synthetase activity 
and 3) by control of the rate of production of the enzyme. The 
mechanism involved in ALA.synthetase degradation has not been reported. 
Several investigators have suggested that heme may . function as a 
negative feedback inhibitor of ALA synthetase. Burnham and Lascelles 
(12) reported that heme markedly inhibited ALA synthetase activity in 
pr,epa:rations from the bacterium, ¢\hodopseudomonas · spheroides. Evidence 
suggesting a similar feedback inhibition was reported to occur in rab-
bit reticulocytes (88); however, Granick (49) found no evidence of 
heme inhibition of ALA synthetase activity in mitochondrial preparations 
isolated from livers of guinea pigs with a chemically induced porphyria. 
Scholnick et al. (129) reported that heme inhibited the activity of 
partially purified ALA synthetase prepared from rat liver. The 
inhibition was blocked by a number of proteins which bind heme, including 
cell sap obtained from normal rat liver. These workers postulated that 
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the latter finding explains previous failure to demonstrate heme in-
hibition in crude systems. 
The rate at which heme is produced also may be controlled by the 
cellular level of ALA synthetase. Granick (4~ postulated a possible 
mechanism for the regulation of ALA synthetase concentrations based on 
studies involving the. use of ALA synthetase inducing compounds. He 
suggests that heme binds with a protein aporepressor, thereby forming 
a holorepressor which inhibits ALA synthetase formation. He further 
postulated that the ALA synthetase inducing chemicals compete with heme 
for the binding site on the aporepressor, forming an inactive holo-
repressor, thus allowing continued synthesis of the enzyme. The half-
life·of ALA synthetase has been reported by Marver et al. (92) as 70 
minutes in rat liver and.by Granick (49) as 4-6 hours in cultured chick 
cells. In ·either instance, its.half-life would be considered relatively 
short, thus the mechanism proposed by Granick (49) for regulation of ALA 
synthetase production would provide a sensitive control mechanism of 
heme biosynthesis. 
' 
Th.e manner in which ALA synthetase may be involved in diseases of 
porphyrin metabolism has been investigated intensively in recent years. 
It has been established that overproduction of ALA synthetase is in-
volved in certain of the hepatic porphyrias and, similarly, in certain 
of the chemically.induced porphyrias (52,50,142). 
Biosynthesis of ,Pbrphobilinogen - :,..._· ~ :!If ·~ The second st'ep in heme biosynthesis is the formation of porpho-
bilinogen (PBG) by condensation of two molecules of ALA (127). The 
existence of PBG was first indicated by the finding of an Ehrlich 
reagent positive substance in urine from patients with acute porphyria 
(148). The observation that uroporphyrin formed spontaneously in urine 
containing high levels of the Ehrlich positive substance suggested the 
possible involvement of this substance as an intermediate in porphyrin 
synthesis. 
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Westfall (33) in 1952, crystallized PBG from the urine of a patient 
with acute porphyria. Using these crystals, Cookson and Rimington (20) 
determined the structure of PBG to be 2-aminomethyl-4-2-carboxyethyl-3-
carboxymethylpyrrole. Proof that PBG is a precursor of heme was demon-
strated by isotope labeling studies using 14c-ALA and 14c-PBG as sub-
strates in separate experiments with in vitro preparations of duck red 
cells 0.27). These experiments also provided proof that PBG was formed 
by the condensation of two molecules of ALA. 
The condensation of two molecules of ALA to form PBG is catalyzed 
by the enzyme, ALA dehydrase (38). This enzyme is locate~ in the 
soluble fraction of the cytoplasm, in contrast to the mitochondrial 
location of ALA synthetase (38,,,51). ' Reduced glutathione, or a similar 
thio-group activator, is required for ALA dehyd7ase activity (38). 
Although ALA dehydrase activity is strongly inhibited by ethylene 
diaminetetra·acetate (EDTA), no requirement for a metal has been 
established (155). Lead also inhibits ALA dehydrase both in vivq_ and 
in vitro by: inactivati~g sulfhydryl groups on the enzyme (36). As a 
result of this inhibition, patients with lead poisoning excrete large 
amounts of ALA (15). 
The rate at which heme biosynthesis occurs is considered to be 
governed primarily by the catalytic activity and catalytic capacity of 
ALA synthetase. The remaining enzymes involved in heme biosynthesis are 
believed to have little influence on the control of heme production 
rates since their catalytic capacities are normally much greater than 
the catalytic capacity of ALA synthetase (141). However, in vitro 
studies with human red cells and mouse liver have demonstrated marked 
inhibition of ALA dehydrase by heme, which suggests the possibility 
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of an additional method of cQntrolling the rate of heme biosynthesis, 
i.e., negative feedback inhibition of ALA dehydrase (13,19). A further 
means of regulating heme production at this step could occur by repres-
sion of synthesis of ALA dehydrase in a manner similar to that which 
has been proposed for c~ntrolling ALA synthetase production. The 
half-life of ALA dehydrase has been reported as 5-6 days (23). This 
relatively long half-life does not favor the latter mechanism as a 
sensitive regulator of heme synthesis. 
Biosynthesis of Uroporphyrinogeri III 
Uroporphyrinogen III. (UROgen III) , the hexahyclroporphyrin of uro-
porphyrin (URO III), is the first tetrapyrrole formed in the heme bio-
synthesis pathway (Figure 1). Fischer correctly hypothesized the 
structure of the oxidized form of UROgen and noted that four isomer 
types (I, II, III and IV) were possible (100). Of the different isomer 
types, only types I and III are known to be formed in biological mate-
rial and only the type III UROgen is utilized as an intermediate in 
heme biosynthesis (9.:>). Evidence suggesting that UROgen III, the re-
duced form of URO III, is the intermediate utilized in heme biosynthe-
sis rather than the oxidized form, URO III, was provided by studies 
which showed that cellular extracts synthesized heme when UROgen III 
was used as a substrate but not when URO III was used (102). Mauzerall 
and Granick (96) provided further evidence by demonstrating that the 
enzyme which catalyzes the subsequent step in heme biosynthesis will 
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use only the reduced form of URO as a substrate. 
Cellular extracts which catalyze the condensation of PBG to UROgen 
III have been obtained from various plants, animal tissues and bacteria 
(95). Two enzymes, UROgen I synthetase and UROgen III cosynthetase, 
both of which are located in the cytoplasm, are required for the forma-
tion of UROgen III. Normally, the type III isomer is the predominate 
UROgen produced and only a small amount of the unusable isomer, UROgen I, 
is formed. That both enzyme components are required for the formation 
of UROgen III was shown by Bogorad (6), who demonstrated that UROgen 
III cosynthetase (UROgen isomerase) is heat labile while UROgen I syn-
thetase (PBG deaminase) is heat stable. He found that untreated plant 
tissue extracts formed only UROgen III and the heated extracts formed 
only UROgen I. He further found that UROgen I formation occurred in the 
heat treated preparations at rates comparable to UROgen III formation in 
the untreated preparations, indicating that the UROgen I synthetase 
enzyme was not affected by the heat treatment. These findings provided 
the basis for Bogorad's hypothesis that the defect in congenital 
erythropoietic porphyria of man and cattle involves a deficiency of URO-
gen III cosynthetase, thus explaining the excessive production of UROgen 
I, which is a prominent feature of this form of porphyria (6,8). 
The exact mechanism by which both enzymes operate to condense 
and cyclize PBG to the usable type III isomer of UROgen, and the possible 
intermediate compounds which may be involved have not been clearly es-
tablished. Bogorad (8) postulated that polypyrryl methane polymers of 
PBG are involved and, in later work (105), reported that tripyrryl 
methane is a likely substrate for UROgen III cosynthetase. 
Although there is no direct evidence in support of a physiological 
control mechanism for regulation of heme synthesis at this step, the 
rate of UROgen III synthesis in avian erythrocytes markedly decreases 
when oxygen concentration rises above or drops significantly below 
seven percent (26). This suggests the possibility that oxygen tension 
may effect an additional control mechanism for the regulation of heme 
production. 
Biosynthesis of Coproporphyrinogen III 
1.2 
The reaction which forms coproporphyrinogen III (COPROgen III) in-
volves step-wise decarboxylation of the four acetic acid groups on URO-
gen III. Decarboxylation is catalyzed by the cytoplasmic enzyme, 
UROgen decarboxylase, and appears to proceed in a random manner by the 
removal of one acetic acid carboxyl group at a time (146). Seven-, six-, 
.and five-carboxyporphyrinogens are produced as UROgen undergoes pro-
gressive decarboxylation. These intermediates have been isolated 
in normal urine and are present in especially large amounts in urine from 
subjects affected with porphyria (17). Vilae and Grinstein have demon-
strated that five- and six-carboxy porphyrinogens III are utilized in 
the formation of heme thus confirming their role as intermediates in 
coproporphyrinogen III formation. 
Either of the type I and III isomers of UROgen can be decarboxyla-
t~d by the enzyme to the corresponding isomer of COPROgen; however, 
the decarboxylation rate of the type III isomer is twice that of the 
type I (95). The reaction in vitro is enhanced by the presence of 
reduced glutathione and by anaerobic conditions (96). 
It is well established that only the reduced form of URO and COPRO 
is utilized in heme biosynthesis. However, Bogorad (7) isolated 
an enzyme from spinach leaves that catalyzes formation of URO from 
UROgen. The significance of this finding is unknown but the reaction 
does not appear to be important in mammalian tissues (124). 
Biosynthesis of Protoporphyrin IX 
Protoporphyrin IX (PROTO IX), a porphyrin of the type III isomer 
series, is the immediate precursor of heme (Figure 1). The formation 
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of PROTO IX results from oxidation of two propionic acid groups on 
COPROgen III to two vinyl groups and the removal of six hydrogen atoms. 
This reaction is catalyzed by the mitochondrial enzyme, COPROgen oxidase, 
which utilizes only the III isomer of COPROgen as a substrate (123). 
The substrate specificity of this enzyme for the III isomer is con-
sidered to be the major reason that only the type III isomer of 
PROTO has been found in biological material. 
The exact reaction mechanism by which COPROgen III is converted to 
PROTO IX has not been clearly defined. Since it has been demonstrated 
that S-hydroxypropionic acid deutroporphyrinogen is converted to PROTO 
IX by bovine liver mitochondria, Sano (121) suggested that this com-
pound is an intermediate in the synthesis of PROTO IX from COPROgen III. 
Porra and Falk (107) proposed that an intermediate having one vinyl and 
three propionic acid groups is first formed in this reaction and then 
converted to PROTO IX. It is not clear whether protoporphyrinogen IX 
(PROTOgen IX) is produced in the reaction and spontaneously oxidizes to 
PROTO IX or whether PROTOgen IX is enzymatically oxidized to PROTO IX. 
That an enzyme may be involved in the process is suggested by the ob-
servation that the rate of oxidation is accelerated in vitro by the 
presence of liver mitochondria (123). 
14 
Biosynthesis of Heme 
The synthesis of heme involves the insertion of ferrous iron into 
the tetrapyrrole ring of PROTO IX (66)·. The mitochondrial enzyme, 
ferrochelatase, catalyzes this reaction, although under the proper con-
ditions, iron will react spontaneously with PROTO IX (45). A variety 
of porphyrins other than PROTO IX and metallic ions other than iron can 
be utilized as substrates by ferrochelatase. Jones and Jones (66) re-
ported that ferrochelatase isolated from Rhodopseudomonas spheroides 
synthesized metalloporphyrins from such substrates as mesoporphyrin, 
deutroporphyrin and hematoporphyrin and incorporated various metallic 
ions including Co-I+, Fe-I+, zn-1+ and Mn-I+ into each of these porphyrins. 
However, ferrochelatase cannot utilize URO, COPRO and PROTOgen as sub-
strates in the formation of metalloporphyrins (81). For maximal .. 
in vitro activity, the enzyme requires an anaerobic atmosphere 
and a reducing agent, presumably to k17ep iron :in the ferrous state (106). 
The observation that relatively low concentrations of heme and 
other metalloporphyrins markedly inhibit ferrochelatase activity in 
Rhodopseudomonus spheroid~ suggests a regulatory mechanism for con-
trolling the rate of heme biosynthesis (66). It has been demonstrated 
in this organism that ALA synthetase is subject to negative-feedback 
inhibition by heme (12); however, ferrochelatase appears to be even 
more sensitive than ALA synthetase .to heme inhibition (66). 
Abnormal Heme Biosynthesis 
Porphyria in Man 
The earliest documented case of porphyria in man was reported in 
1874 (131). The patient was a 33 year old man who had suffered from 
cutaneous photosensitivity since infancy. Two pigments, designated as 
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urorubrohematin and urofuscohaematin were extracted from the patient's 
urine (4). The absorption spectrum of one of those pigments was found 
to be similar, but not identical, to that of hematoporphyrin. At 
autopsy, the most notable findings were reddish brown discoloration of 
the skeleton and enlargement of the spleen. The clinical history, 
chemical findings, and the pigmented skeleton indicate that the condition 
was the type of porphyria now designated as congenital erythropoietic 
porphyria. 
In 1889, Stokvis (138) documented a case report of a patient who 
began voiding reddish urine after treatment with a newly introduced 
hypnotic drug, Sulphonal. During the following years additional cases 
were described in which treatment of patients with Sulphonal and other 
similar hypnotic drugs was followed by the voiding of red urine, 
designated as haematoporphyrinuria,' and, in some instances, also by 
neurologic .disturbances (46). ..Howev.er, hypnotic drugs were not involved 
in all.cases of haematoporphyrinuria and the incidence of this condition 
was relatively low in patients receiving the drugs. Rankin and Par-
dington (46) reported the occurrence of central nervous system distur-
bances in conjunction with haematoporphyrinuria in two unrelated women, 
neither of whom had taken Sulphonal. The clinical symptoms and the 
pigmented urine observed both in the drug induced and spontaneous cases 
of haematoporphyrinuria are compatible with the features now recognized 
as being characteristic of certain types of hepatic porphyrias. 
Photosensitivity has long been recognized as one of the major 
clinical features of various types of porphyria. Anderson (3) is given 
credit as being the first to note the relationship between the occur-
rence of photosensitivity and the abnormal excretion of porphyrins in 
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the urine. He described.the skin lesions of photosensitivity in two 
brothers, both of whom excreted .haematoporphyrin in the urine. Meyer-
Betz vividly .demonstrated .that porphyrins could induce photosensitivity 
. in a classic experiment in .which. he .. injected himself with 200 mg of 
haematoporphyrin.and.subsequently,exposed.his hands and face to sun-
light. The exposed.areas of-skin-developed urticaria and severe edema. 
The photosensitivity persist.ed -for two .months. after the injection. 
In 1911, Gunther (5.5) classified the diseases of porphyrin meta-
bolism under four categories: 1). hematoporphyria acuta, 2) hemato-
porphyria acuta toxica, 3) hematoporphyria chronica, and 4) hemato-
porphyria congenita. In a later report, he provided further support 
for this classification scheme and suggested that hematoporphyria acuta 
is an inherited disease. (56) •.. Gunth~r .. also described spontaneous 
cases of hematoporphyria acuta.and cases of hematoporphyria toxica 
associated with the use.of Sulphonal, Trional and Verona!. The de-
scription of hematoporphyria.congenita given by Gunther is cited by 
Garrod.(35). .as the first.recognition .. that this disease is an "inborn 
error of metabolism". 
The research of. Hans Fischer and co.,.,workers (29 ,28,30 ,31) estab-
lished the structural difference between haematoporphyrin and protoheme. 
This led Walsenstrom (147) to propose a new classification for the dis-
eases of porphyrin metabolism. Waldenstrom used the term porphyria in 
place of haematoporphyria and grouped the diseases into three categories: 
1) porphyria congenita, 2) porphyria cutanea tarda, and 3) porphyria 
acuta. Additional knowledge gained during the past two decades has 
led to the subdivision of the hereditary porphyrias into the two major 
categories, hepatic and erythropoietic, with subdivisions of each type 
(124) • 
. . Erythropoietic Porphyria. 
Congenital Erythropoietic Porphyria. Congenital erythropoietic 
porphyria (CE~) is the rarest form of the hereditary porphyrias. The 
total number of recorded cases of this type of porphyria in man through 
1965 was reported as 60 by Schmid (124). Although the rarity of the 
condition precludes detailed genetic analysis, the evidence indicates 
that the disease is transmitted as an autosomal recessive trait (124). 
Eventhough the condition is rare, the genetic defect is distributed 
among various races of widely differing genetic background including 
Caucasian, Japanese, Bantu, Sudanese, Aleutian Indian and Asiatic 
Indian (124). 
' The erythropoietic nature 'of CEP was suggested in an early study 
when cells from the bone.marrow of a patient with the disease was exam-
inedby fluoresc;ence microscopy and found to exhibit intense.red fluore-
scence indicating the presence of porphyrins (9). Schmid et al. (125) 
later confirmed this finding in other cases of the disease and further 
noted that the bone marrow cells which exhibited fluorescence were 
primarily normoblasts although weak fluorescence was detected in non-
nucleated polychromatophilic erythrocytes in marrow and circulating 
blood. The nuclei of fluorescing normoblasts exhibited much more 
intense fluorescence than the cyto~lasm. Many fluorescing nuclei also 
contained large heme inclusion bodies which were not·observed in non-
fluorescing normoblasts. They estimated that 30 to 70 percent of the 
total population of normoblasts contained abnormal levels of porphyrins. 
Since both fluorescing and non-fluorescing normoblasts were observed in 
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all patients, it was postulated that two distinctly separate erythroid 
cell populations existed, i.e., a normal cell line which were non-
fluorescing and a fluorescing cell line containing the defect (125,126). 
Similar findings of fluorescing and non-fluorescing erythroid cells were 
noted in marrow of cattle with CEP (120). Recent studies of bone marrow 
from porphyric cattle in which erythropoiesis was accelerated by bleed-
ing have shown that a marked increase in percentage of fluorescing 
normoblasts occurs during the period of stimulated erythropoietic acti-
vity (120). This finding is considered as evidence against the two cell 
line theory. If two separate cell lines exist, it would be expected 
that both cell lines would be stimulated to a comparable degree. 
The metabolic defect in CEP results in excessive production of URO 
and COPRO,which accumulat~ in the developing erythroid cells and plasma, 
are deposited in teeth and boue and are excreted in urine and feces 
(126, 124). These, porphy:dns impart a pinkish to brown.ish pigmentation 
of the s:k~letal tissue. and brownish to reddish discoloration of .. urine 
and are responsible for the characteristic·bright reddish fluorescence 
when exposed to ultraviolet light. Additional clinical features include 
photosensitivity and anemia (145,46,124). 
Both the types I and III isomers of URO and COPRO are produced in 
excessive amounts; however, the major share of these porphyrins is 
represented by the unusable type I isomer (62,17). The predominant por-
phyrin present in erythrocytes and urine is URO while COPRO constitutes 
the major porphyrin i• Teces (77,124). The porphyrin precursors, ALA 
~nd PBG, are.not elevated in tissues.or excreta (124,152). 
Photosensitivity and anemia are common manifestations in patients 
with GEP. The degree of photosensitivity and anemia varies considerably 
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among affected individuals as well as in the same individual at dif-
ferent times (145,80,54). Photosensitivity results from effects of the 
photodynamic properties of the excess porphyrins in tissues. The 
exact cause and mechanism responsible for the anemia is not clear; al-
though it is generally considered to be of hemolytic nature resulting 
from an intracorpuscular defect possibly related to the high concentra-
tion of porphyrins found in the erythrocytes (124). Erythrocyte life 
span studies made in a limited number of cases have yielded equivocal 
results; however, a shortened red cell survival time was observed in 
some of the cases studied (80,89,145). 
The site of the defect in the porphyrin biosynthesis pathway and 
the mechanism responsible for overproduction of the type I isomer of 
URO and COPRO in CEP have been the subjects of considerable speculation 
during recent years. The demonstration by Bogorad (8) that two enzymes 
were involved in the conversion of PBG to U:Ro'gen III and that, in the 
absence of the second enzyme, only UROgen I was formed, led him to sug-
gest that the metabolic defect in CEP was due to impaired UROgen III 
cosynthetase activity, or increased activity of UROgen I synthetase, or 
a combination of both. Watson (150) later proposed that the defect 
involved an overproduction of ALA synthetase, thus leading to over-
loading of the physiologically imbalanced dual enzyme system and favors 
increased production of UROgen I without impairment of UROgen III pro-
duction. However, no direct evidence has been presented in support 
of this hypothesis. 
Romeo and Levin (118) have recently reported evidence indicating 
that at least one of the primary defects in the metabolic pathway in-
volves a deficiency of UROgen III cosynthetase activity. In further 
studies, Romeo et al. (117) demonstrated that individuals heterozygous 
for the CEP trait have cosynthetase activity intermediate between 
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that of normal and affected individuals. Although a deficiency of this 
enzyme would explain the major biochemical features of CEP, 
it remains to be proven whether or not other defective mechanisms may 
also be involved. 
Erythropoietic Protoporphyria. Erythropoietic protoporphyria (EP) 
is a second type of porphyria in which a defect in porphyrin metabolism 
occurs in erythroid cells (57,109). This type of porphyria was first 
clearly defined in 1961 by Magnus et al. (91) as a distinctly separate 
entity. However, description in earlier case reports suggested the oc-
currence of EP as early as 1953 (79). Haeger-Aronsen and Krook (58) 
surveyed all the known cases of EP in Sweden and confirmed the previous 
assumption that the disease is inherited and that the gene is dominant 
(57). Other workers have stated that available data exclude simple 
autosomal dominant, x-chromosome linked, and autosomal recessive in-
heritance, and suggest a multifactorial inheritance or an incomplete 
dominant form of inheritance (159). 
The primary clinical symptom of the condition is a mild to moderate 
photosensitivity manifested early in life, usually in the first two 
years (109). Affected individuals are generally less photosensitive 
than those affected with CEP. Anemia is not present in protoporphyria; 
however, there is sufficient evidence to indicate defective heme bio-
synthesis in erythroid cells. 
The more classical cases of EP are characterized by the presence of 
large amounts of PROTO IX in erythrocytes, bone marrow, plasma and feces 
(109, 91, 58). Many of the red cells exhibit intense fluorescence due 
to the high intracellular PROTO content (109,21). Concentrations of 
URO and COPRO are within normal limits in tissues and excreta. 
Although protoporphyria is classified as an erythropoietic type, 
some studies have yielded results which suggest that defective porphyrin 
metabolism in EP patients occurs in other tissues as well as in erythroid 
cells. The elevated erythrocyte PROTO is indicative of an erythropoietic 
origin of the defect. Porter (108) demonstrated that bone marrow from 
two EP patients incorporated 59Fe into heme at rates 10 to 20 fold 
greater than did normal marrow and that heme synthesis in hepatic tissue 
from the same patients was normal. However, other investigators have 
pointed out that, since erythrocyte life span is normal in EP patients, 
all the fecal PROTO could not be derived from circulating red cells (130). 
Scholnick.et al. (130) recently reported the results of an experiment 
using a double isotope labeling procedure in an EP patient in which they 
interpreted the findings to indicate that excessive PROTO production 
occurs in hepatic tissue as well as in erythroid cells. 
Hepatic Porphyrias. The hepatic porphyrias represent a much more 
important group of porphyric diseases than the erythropoietic types in 
man primarily because of their much higher incidence and generally more 
severe clinical manifestations. Characteristic features which are com-
man to all of the hepatic porphyrias include: 1) autosomal dominant 
inheritance, 2) failure of symptoms to become apparent before a few 
years of age, commonly developing during middle age, 3) overproduction 
of type III isomer of porphyrins, and 4) excessive urinary excretion of 
the porphyrin precursors, ALA and PBG. Each of the separate types of 
hepatic porphyria, however, are characterized by differences in degree 
and pattern of expression of the above features as well as by additional 
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features not common to all types. 
Acute Intermittent Porphyria.. Acute intermittent porphyria (AIP) 
is the most common form of porphyria in man (46). The disease is found 
among various races but has especially high incidence among people of 
Scandinavian origin (14). Waldenstrom established the inherited nature 
of the disease and Qates (34), in a review of Waldenstrom's data, be-
lieved the transmission of the porphyric trait occurred through an ir-
regular dominant gene. Later studies suggest that transmission of AIP 
occurs through a rare single autosomal gene (46). Analysis of genetic 
data by other workers indicates that most affected individuals are 
heterozygous for the dominant autosomal gene (46). 
The principal clinical feature of AIP is reflected in the name 
designation of the disease, i.e., acute attacks followed by periods of 
latency. Additional clinical features include neurologic dis-
turbance such as mental depression, neuritis, obscure abdominal pains 
and periods of insanity (87). The onset of symptoms in affected females 
commonly occurs in the third decade of life, while in males, initial 
symptoms more commonly occur during the fourth decade (46). It was noted 
in early studies of AIP that acute attacks are often precipitated by 
certain drugs, including the barbiturates, as well as non-drug related 
factors such as menstruation, alcoholism and infections (124, 87). 
The primary biochemical features of AIP are elevated urinary levels 
of ALA and PBG which are especially high during acute attacks (141,1). 
During latent periods of the disease, ALA and PBG levels are variable 
and may be normal to elevated. Porphyrins are usually present in only 
small amounts in the freshly voided urine. However upon standing, any 
porphyrinogens present may be oxidized to porphyrins and some of the PBG 
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may be converted spontaneously to URO (152). Fecal COPRO and PROTO 
levels may be slightly elevated during acute attacks (124). Large 
amounts of PBG are regularly found in liver tissue from patients with 
AIP (126). The levels of PBG in bone marrow and spleen are normal thus, 
giving further indication that erythropoietic tissues are not involved. 
The relationship between the biochemical findings and neurologic 
symptoms.is intriguing but no direct evidence has been found to indicate 
that elevated levels of ALA and PBG produce neurologic lesions (53). 
The cause of the neurologic signs associated with AIP remained une~­
plained. 
It was demonstrated by Tschudy et al. (143) and Rose et al. (119) 
that a high carbohydrate diet had a protective effect in rats against 
the porphyrin inducing capacity of porphyrinogenic drugs. This ob-
servation led to the use of high carbohydrate·diets in patients affected 
with AIP for protection against and decreasing severity of acute attacks 
(153). In general, such diets have a favorable effect toward alleviation 
of neurologic symptoms and reduce the urinary excretion of the porphyrin 
precursors. The protective effects of carbohydrates has been 
termed the "glucose effect". 
It was shown by Granick (49) that an overproduction of ALA synthe-
tase was involved in drug-induced hepatic prophyria in experimental 
animals and led him to suggest that a similar metabolic disturbance may 
be involved in the hepatic porphyrias of man. Tschudy et al. q42) 
later found that patients affected with AIP showed marked increase in 
hepatic ALA synthetase activity. This finding provided the initial 
proof that an overproduction of ALA synthetase is responsible for the 
excessive production of ALA and PBG and prompted these workers to define 
the condition as an "overproduction disease". More recently, Strand 
et al. (139) demonstrated marked reduction in the rate of conversion 
of PBG to porphyrins as well as increased ~A synthetase activity in 
hepatic tissue from AIP patients. On the basis of this finding, they 
suggest that a deficiency of UROgen I synthetase activity may be re-
sponsible for a decrease in PBG utilization and that the elevation in 
ALA synthetase activity results from inadequate heme synthesis in 
hepatic tissue so that heme repression of ALA synthetase production is 
decreased. 
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Kappas .et al. (75) recently demonstrated that plasma obtained from 
AIP patients during acute attacks induces porphyrin synthesis in chick 
embryo liver cells in vitro while plasma from normal individuals and 
plasma from AIP P.atients in remission failed to show this effect. They 
speculated that circulating steroid hormones were possibly responsible 
for this effect, since·it has been shown that certai~'steroids and 
steroid metabol'ites, as well as plasma from normal individuals taking 
oral contraceptives, stimulates porphyrin synthesis in the chick embryo 
cell system (74,113). The physiologic role that steroids may play 
in the control of porphyrin synthesis has not been established; however, 
there is mounting evidence that they do have an important effect on both 
normal and abnormal porphyrin metabolism (48.). 
Hereditary Coproporphyria. The first recognized cases of hereditary 
coproporphyria (HC) were reported in 1953 in a boy and both of his 
parents (5). These cases were recognized as being distinctly different 
from previously recognized cases of AIP in that a prominent f~ature of 
the disease was excretion of large amounts of COPRO III in ur~ne and 
feces. Many additional cases of HC have since been describe4 ind the 
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chemical and clinical features of the disease have been well charac-
terized (47). 
Hereditary coproporphyria is inherited as a simple Mendelian auto-
soma! dominant trait (47). Clinical signs of the disease are essentially 
the same as those in AIP; i. e., abdominal pain, mental disorders, neuro-
logical signs, vomiting and constipation (47,76). Although photo-
sensitivity is not a usual feature of the disease, it has been described 
in at least one HC patient (47). The disease is similar to AIP in that 
it is characterized by acute attacks followed by periods of remission 
and also in that administration of certain drugs may precipitate acute 
attacks (47,76). 
The principle chemical findings in affected individuals are greatly 
elevated fecal levels of COPRO III and large amounts of ALA and PBG in 
urine, especially during acute attacks. Usually, the urinary levels of 
URO and COPRO, the fecal PROTO and the blood pdrphyrin levels are 
normal (47). Typical porphyrin fluorescence has been demonstrated in 
hepatic tissue by fluorescence microscopy. 
Recent studies regarding activities of enzymes involved in heme 
bio~ynthesis indicate markedly increased hepatic ALA synthetase activity, 
moderate increase in hepatic ALA dehydrase activity and possibly a slight 
increase in hepatic ferrochelatase (76). Mcintyre et al. (98) have 
found that hepatic ALA synthetase activity was normal in a patient with .. 
HC in remission. These investigators also reported increased urinary ,. 
excretion of 17-oxosteroids and increased ALA dehydrase activity in 
blood from two HC patients during acute attacks of the disease. Urinary 
levels of 17-oxosteroids and blood ALA dehydrase activity were found 
to be normal in HC patients during remission. The significance of 
elevated urinary steroids during acute attacks .is not known; however, 
it suggests a possible influence of steroid hormones in this disease 
as well as in AIP. 
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Porphyria Variegata~. -Porphyr.ia-variegata (PV). occurs most commonly 
among the Africaner population.in South Africa; however, the condition 
is not limited to this group and has been reported in various other 
parts of the world (59,157). Geneti~ studies among the Africaner popu-
lation indicate that the disease is-inherited as an autosomal dominant 
trait and results from a single dose of an abnormal gene (22). The 
disease usually does not become apparent prior to the third decade of 
life (124). 
Most of the clinical features of.PV are similar to those of AIP 
and HC, including neurological manifestations and acute attacks, which 
may be precipitated by certain drugs followed by periods of latency 
(22,25). Photosensitivity is.a common feature of this diasease and is 
present in approximately one~half of the cases of PV (124). 
The chemical.featuress of PV show both similarities and differences 
to the other hepatic porphyrias .. Urinary excretion of ALA and PBG is 
markedly increased with.URO.and COPRO being only mildly elevated (124). 
Fecal excretion of .URO, COPRO and.PROTO are markedly elevated. Con-
centrations of the porphyrins.in feces and porphyrins and porphyrin 
precursors in urine increase considerably during acute attacks (124). 
Porphyrin levels in red cells and bone marrow are normal. 
Studies of the enzymes involved in the heme biosynthesis pathway 
in individuals affected with PV thus far have been confined to hepatic 
ALA synthetase. The activity of this enzyme has been shown to be in-
creased in hepatic tissues from patients with PV (139). The rate of 
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utilization of PBG by hepatic tissue has been found to be normal (139), 
a feature differing from that in AIP. 
Cutaneous Hepatic Porphyria. Cutaneous hepatic porphyria (CHP), 
often referred to as porphyria cutanea tarda, occurs with relative fre-
quency among the Bantu natives of South Africa but is not limited 
to this ethnic group (124). A great deal of controversy exists regar-
ding whether or not this disease is inherited or acquired. Although 
there are strong indications that the disease is inherited or, at least, 
that there is an inherited predisposition, genetic studies have not 
yielded evidence that clearly demonstrates an heritable nature of the 
disease (24). In most instances, a concurrent liver lesion, especially 
that produced by chronic alcoholism is present at the time the disease 
becomes clinically apparent (46,141). This has led to the belief by 
some that the disturbance in porphyrin metabolism is a secondary effect 
(46). Others believe that alcoholism does not cause the porphyrla, but 
merely aggravates the pre-existing metabolic defect (116). 
Onset of CHP is marked by photosensitivity and usually does not 
occur prior to middle age (124). The condition differs from the other 
hepatic porphyrias by the absence of neurological manifestations. 
Chemical features of CHP are increased urinary and fecal excretion 
of URO and COPRO,without elevations in the porphyrin precursors, ALA 
and PEG (116,160). Fecal PROTO levels may be increased but the levels 
are not comparable to those found in cases of PV (116). Erythrocyte 
and bone marrow porphyrin levels are normal; however, pla$ma ponphyrin 
levels are often elevated (46). 
Zail and Joubert (160) have studied hepatic ALA synthetase activity 
in 12 cases of CHP. Five of these cases showed slightly elevsted ALA 
synthetase activity while seven showed activities within normal range. 
Kaufman and Marver (76) studied the activities of ALA synthetase, ALA 
dehydrase and ferrochelatase in a single liver biopsy specimen 
from a patient with CHP and determined the activity of each of these 
three enzymes to be normal. 
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Of the four types of hepatic porphyria, CHP is the only one in 
which hepatic ALA synthetase activity is normal. This feature is com-
patible with the normal ALA and PBG levels observed in the urine of 
patients with CHP. However, the explanation for the large amounts of 
porphyrins excreted by these patients remains to be determined. 
Rimington et al. (61) has postulated that the excessive porphyrin 
formation results from an increased rate of oxidation of the porphyrino-
gens to porphyrins by the liver. A number of cases of CHP have been 
reported in which no porphyrinogens were found in excreta, as well as 
cases in which both porphyfinogens and porphyrins were found (63,72). 
These contrasting findings suggest the possibility that more than one 
mechanism may be involved. 
Porphyria in Animals 
Hereditary porphyrias are relatively rare among domestic animals 
and have thus far been reported only in the bovine, porcine and feline 
species. The type 9f porphyria in each of these species is of the 
erythropoietic type and most closely corresponds to congenital erythro-
poietic porphyria of man. However, certain features of the disease in 
animals differ from those in man and differ between each of the animal 
species. 
There have been no disturbances in porphyrin metabolism of an in-
herited nature among animal species that correspond to the hepatic types 
of porphyria in man, However, chemically induced porphyria in experimen-
tal animals bears close resemblance to the disease induced by the same 
chemical agents in man. Since the heme biosynthesis pathway apparently 
is identical in all animals, there is no reason to suspect that similar 
genetic defects involving the pathway could not occur in animals as well 
as man. Although not considered to be a disease in the usual sense, 
physiologic peculiarities in porphyrin metabolism are characteristic of 
certain species including the American fox squirrel and certain rodents. 
Bovine Porphyria. Porphyria is much more commonly encountered in 
cattle than in other domestic animals. The disease in cattle is almost 
identical to congenital erythropoietic porphyria in man. The first 
recognized cases in cattle were reported in 1936 by Fourie (32) who de-
scribed the disease in ~.herd of Shorthorn cattle and recognized simi-
larities to the disease· in man. However, reports in the literature as 
early as 1910 recorded the observation of chocolate colored bones in 
cattle carcasses (32). Additional observations of abnormally pigmented 
cattle bones were published in the following years (32), but it was 
not until Fourie's early observations that the disease was described in 
living animals. During subsequent years; bovine porphyria has been re-
ported in various breeds of cattle in various parts of the world (2,103, 
69,112,111). Through an extensive series of studies, Fourie (32,33), 
in collaboration with Rimington (115,114), characterized the principal 
clinical, clinical, genetic and chemical features of the bovine disease. 
Bovine porphyria, like its counterpart in man, is inherited as a 
simple Mendelian recessive trait (33). The genetic trait apparently 
is relatively common among the Holstein-Friesian breed in the United 
States as a result of widespread use of three bulls heterozygous for 
the trait (149). The total number of offspring1 sired by these bulls 
is unknown but is estimated to be over 100,000. - Fifty percent of the 
offspring would be carriers .of-the defective gene. 
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Like its counterpart in man, bovine porphyria is characterized 
clinically by photosensitivity, anemia, pigmentation of teeth and bone 
and the passage of red urine due to the presence of excessive porphyrins 
(32,149). Similarly, most of the chemical features that characterize 
bovine porphyria are identical to those of CEP in man (151,2,67). How-
ever, bovine porphyria differs from its counterpart in man in that PROTO 
IX is markedly elevated in red cells and in bone marrow (151,16). The 
significance of the elevated erythrocyte PROTO levels has not been 
clearly established. It could be indicative of a difference in the de-
fective mechanisms of porphyrin-metabolism in the disease of man and 
cattle; however, Goldberg and Rimington (46) observed that normal bovine 
red cell hemolysates are capable of synthesizing greater amounts of 
PROTO than hemolysates of normal-human red cells. These authors suggest 
that the species difference in erythrocyte PROTO levels arises because 
cattle red< cells retain functional mitochondrial elements for a longer 
period during maturation than do human red cells. Smith and 
Kaneko (137) suggested that the maturation rate of immature bovine red 
cells taken from porphyric cattle is much slower than the: maturation 
rate of reticulocytes from phenylhydrazine-induced anemic cows. 
Levin (84) has demonstrated a deficiency in UROgen III cosynthetase 
activity of red cells from porphyric cattle identical to that demonstra-
ted in man (118). Although a deficiency of this enzyme could explain 
most or all of the chemical abnormalities observed in this type of por-
phyria in cattle and man, definitive information regarding activity of 
other enzymes in the heme biosynthesis pathway and their possible in--
volvement in defective porphyrin metabolism have not thus far been re-
ported in either species. 
The economic significance of the widespread distribution of the 
porphyric trait among cattle of the Holstein-Friesian breed has led to 
investigation directed . toward .. detecting. methods of identifying the 
heterozygous carriers of the porphyric trait. Various approaches to 
this problem have been used by,different investigators. Kaneko and 
Mills (73) demonstrated that glutathione stability is greatly reduced 
in erythrocytes obtained from adult carrier cattle as well as adult 
porphyries; however, glutathione stability was.found to be normal in 
young porphyric cattle. Moore et al. (101) found that carrier 
cattle generally showed significantly larger ratios of COPRO I to COPRO 
III in the urine. Levin (llV) has shown that adult heterozygous cattle, 
as well as man, have a: reduced Urogen III cosynthetase activity level 
in red cells intermediate between those in porphyric and normal indivi:-
duals. Although each of .the.tests show statistically significant dif-
ferences between the normal and heterozygous individuals, technical 
difficulties in conducting.the tests as well as the degree of inaccu-
racy in detecting all heterozygote individuals makes these tests in-
appropriate for routine use. 
Porcine Porphyria. The first live cases of porcine porphyria were 
reported in New Zealand in 1944 (18); however, as in cattle, discolora-
tion of bones in swine at abattoirs ·had been noted previously·(70). 
Further cases of porcine porphyria were later reported in Danish swine 
in 1956 (68). Fairly extensive studies by Jorgensen and With (68,69, 
158,70) were made in the Danish swine concerning the clinical, chemical 
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and genetic characteristics of porcine porphyria. Their studies revealed 
both similarities and differences between porcine porphyria and the 
congenital erythropoietic porphyria of man and cattle. The disease in 
swine was found to be .. inherited .. as .. an. autosomal dominant trait, being 
completely different .in this respect from the similar disease of man 
and cattle (68). A further difference of the disease in swine is the 
absence of photosensitivity (68). Porcine porphyria is similar to CEP 
in man and cattle with respect to porphyrin pigmentation of bone 
and teeth, urinary excretion of relatively large amounts of URO and 
COPRO, increased amounts of porphyrins in blood and other tissues, and 
a predominance of the type I isomer of porphyrins in urine and tissues 
(68,158). The indications from these investigations are that porcine 
porphyria is erythropoietic in type being most comparable to CEP in 
man and cattle; however, certain features such as fluorescence of red 
cells, levels of porphyrins in bone marrow and enzyme studies have not 
been determined in porphyric swine. The experimental herd of Danish 
swine died out before further studies could be conducted and 
other porphyric swine have not since become available for experimental 
study. 
Feline Porphyria. Porphyria in.the domestic cat (Felis catus) 
was first reported in 1964 (140). The original report described brown-
ish pigmentation of the teeth and discolored urine which contained 
excessive amounts of URO, COPRO and PBG, Only one other case of 
feline porphyria in cats unrelated to those in the original report has 
been recorded (40). However, further studies of feline porphyria have 
been continued in the colony of porphyric cats established from the 
dam of kittens involved in the first reported case. 
The inheritance pattern of feline porphyria as in swine has 
been established to be autosomal dominant (41). Clinical features of 
the feline disease, in addition to pigmentation of teeth and bone 
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and excessive excretion of ut:inary porphyrins., .. include absence of 
photosensitivity and a mild to moderate .anemia in the more severely 
affected individuals (39,43). The chemical findings in feline por-
phyria are similar to those in CEP of man, cattle and swine in that 
the type I isomer of URO and COPRO predominates in urine, feces, bone 
and various soft tissues (39). Feline porphyria differs from CEP in 
the other species in that excessive quantities of PBG are excreted in 
the urine and differs from CEP in man in that erythrocyte PROTO levels 
are markedly increased (39) • 
. ·Additional biochemical features of feline porphyria are the sub-
ject of the investigations beingreported in the present thesis. 
"Physiological" Porphyria 
The .American foxLsquirrel.(Sciurus niger) appears to have a "physi-
ological" porphyria which mimics many of the features of congenital 
erythropoietic porphyria in other animal species and man (46). The 
condition is a species peculiarity existing in all individuals of the 
species and does not appear to affect the health of the animals. Tur-
ner (144) in 1937, described the condition in the fox squirrel and 
characterized the primary.features which include brownish pigmentation 
of bone and teeth and porphyrinuria. He identified the skeletal chromo-
phore as URO I. Rimington (46) demonstrated the characteristic pinkish 
pigmentation of bones and teeth and confirmed Turner's earlier finding 
that the porphyrin .was primarily URO. Recently, Levin and Flyger (85) 
have shown that UROgen III cosynthetase activity in red cell hemolysates 
and in other tissues .. from .fox squirrels is . much less .. than in similar 
preparations from grey squirrels (Sciurus carolinensis). Low activity 
of this enzyme explains the production of large amounts of URO I by the 
fox squirrel and indicates that the species peculiarity of porphyrin 
metabolism in the fox squirrel is analogous to the inherited defect which 
is responsible for CEP in man and cattle. 
Certain other rodents, particularly the white rat, exhibit the 
peculiar physiologic feature of formation of large amounts of PROTO in 
the glands of Harder which are associated with the lachrymal apparatus 
(46). Strand_et al. (139) have shown that ALA synthetase activity in 
this tissue is extremely high, ranging from 14,005 to 22,250 picomoles 
ALA/mg protein/hour as compared to ALA synthetase activity in hepatic 
tissue of 2.6 picomoles ALA/mg protein/hour. Such levels are much 
higher than those found in hepatic tissue from human patients with acute 
intermittent porphyria. The physiologic dgnificance of the large 
amounts of PROTO in the glands of Harder of the rat is not known. 
Also of interest is the presence of large amounts of the copper 
complex, turacin, deposited in t:he feathers of the touraco bird (:M:uso-
phagidae), which is responsible for the deep red pigmentation in their 
flight feathers (124). There seems to be nothing otherwise unusual 
about the porphyrin metabolism of these birds. 
CUAPTER III 
MATERIAL AND METHODS 
The investigation. was .. conducted .. in two phases. Phase I consisted 
of characterization.of the porphyrins and porphyrin precursors ex-
creted in urine and porphyrins present in erythrocytes of porvhyric and 
nonporphyric cats. Phase II consisted of enzyme studies in tissues 
obtained from affected .and nonaffected cats. The specific enzymes and 
the tissues in which their catalytic activity was determined included: 
ALA dehydrase in erythrocytes, .liver,.and bone marrow; ALA synthetase 
in liver and bone marrow; .. and ferrochelatase in bone marrow. The 
assays for ALA dehydrase and ALA synthetase activities in liver and in 
blood were conducted in separate groups of cats fo.r each tissue type 
assayed for each enzyme. All three enzymes were assayed in the same 
marrow specimen from each individual.animal in which marrow assays 
were conducted. 
Experimental Animals 
A total of 35 male and female porphyric cats, ranging in age from 
six months to eight years were used in the various studies included 
in the two phases of these investigations. Fifty-one healthy male and 
female nonporphyric cats, .:aged six months to seven years were used as 
controls. Prior breeding trials indicated that the majority of the 
porphyric animals used were heterozygous for the porphyric trait. The 
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~everity of the porphyric condition was estimated by an arbitrary gra-
ding system based on visual observation of the relative degree of por-
phyrin pigmentation in the teeth at two to three months of age. Grade 
1 designates animals with the mildest degree of teeth pigmentation. 
Grades 2, 3, and 4 represent increasing degrees of severity respectively. 
The nonporphyric animals used in the blood and urinary porphyrin 
studies were maintained in the porphyric cat colony for six months or 
longer prior to and during the studies. Nonporphyric cats used in the 
enzyme studies were obtained from an animal shelter and from a colony 
maintained for viral research. Since many of the porphyric cats were 
mildly to moderately anemic, three of the nonporphyric cats used in 
the marrow studies were intentionally made anemic by repeated bleedings 
and two nonporphyric cats were used that had an anemia of unknown 
cause. The hemogram for each animal used in the enzyme studies at the 
time of utilization is given in Appendix Table XlII. 
Porphyrin and Porphyrin Precursor Analysis 
Porphyrins and Porphyrin Precursors in Urine and Porphyrins in 
Erythrocytes 
Individual urine specimens for the 24-hour determination of urinary 
porphyrins and porphyrin precursors were collected from each of five 
porphyric cats and five nonporphyric cats over a four day period. The 
urine was collected in 0.5 gm of sodium bicarbonate by means of a stain-
less steel metabolism cage. The specimens were analyzed immediately 
following the 24-hour collection period. 
Fifteen ml of blood for blood porphyrin determinations was col-
lected in ammonium and potassium oxalate anticoagulant (156). A 
hemogram was performed on each sample before assay for porphyrins. 
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URO, COPRO, and PROTO were isolated from urine and red cells by standard 
differential solvent extraction methods (104). A Model III Turner 
fluorometer was used to determine concentration of porphyrins in the 
final extracts. ALA and PBG were.isolated from urine by ,ion exchange 
chromatography and measured as. described by Mauzerall and Granick (97). 
Isomer Analysis of Coproporphyrin 
The ratio of I and III isomers of COPRO from the urine were deter-
mined in one porphyric cat and from red cells of one porphyric cat using 
a modification of the thin layer chromatography system reported by Jen-
sen (65). The modification included use of a different proportion of 2, 
6-lutidine and water (30: 9.75) and the placing of a paper wick in the 
beaker of 30 percent NH40H.to aid in saturation of the atmosphere in 
the developing chamber .. Preparation of thin layer plates and spotting 
of the samples was.done as-described by.J'ensen. Thin layer plates were 
developed in the dark until the solvent front reached the top of the 
plate then removed from.the developing chamber and dried.. Fluorescent 
spots corresponding to the.location of.I and III COPRO isomer standards 
were outlined under ultraviolet light. The silica gel in each area was 
scraped into separate 15 ml conical centrifuge tubes containing 1.5 ml 
of 1.5 N HCl. After mixing by vortex for one minute, each suspension 
was set in the dark for.0.5 hour then centrifuged at 2,000 x g for 10 
minutes. The relative amount of each isomer was determined by measuring 
the intensity of fluorescence in the supernartt ~sing a Turner fluoro-
meter equipped with a high sensitivity attachment. 
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Enzyme Assays 
A total of 26 porphyric and 43 nonporphyric cats were used in the 
enzyme studies. A hemogram was performed on each cat before tissues 
were taken for enzyme analysis. Nonporphyric cats were not used as 
normal controls if any of the hemogram values were outside the normal 
range. Both porphyric and nonporphyric cats were killed by an intra-
thoracic injection of 400 mg of sodium pentobarbital. Liver, bone 
marrow, and blood were removed immediately after the animal was anes-
thetized. The tissues were held at 4° C during preparation for analysis. 
Fixed-time incubation periods were used in determining the activity 
of the various enzymes. The rate of reaction for assay of each enzyme 
was linear with respect to the concentration of enzyme preparation and 
to the length of time the incubation period (Figure 2). 
ALA Synthetase Activity in Liver 
ALA synthetase activity was assayed in liver of three porphyric 
and eight nonporphyric cats by the method of Marver et al. (93). Five 
grams of liver were homogenized in a glass Ten Broeck homogenizer in 
three volumes of 0.9 percent sodium chloride solution which contained 
0.5 mM EDTA and 10 mM tris buffer pH 7.4. The incubation mixture con-
tained 1.0 ml of homogenate, 200 micromoles of glycine, 20 micromoles 
of EDTA, 150 micromoles of Tris-HCl buffer pH 7.2 and 0.4 micromoles of 
pyridoxal phosphate giving a total volume of 2 ml. Incubations were 
carried out in 25 ml erlenmeyer flasks. Six flasks in duplicate were 
used to insure sufficient material for chromatography. The flasks were 
shaken in air for 1 hour at 37° C and the reaction was terminated by 
the addition of 0.5 ml of 25 percent trichloracetic acid (TCA) to each 
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flask. The contents of the six flasks were combined and the precipi-
tate removed" by centrifugation. 
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Nine ml of supernant were transferred to a 50 ml volumetric flask, 
and the aminoketones were.converted to py:rroles.by the addition of 9 ml 
of lM sodium acetate buffer pH 4.6 and 0.225 ml of.acetylacetone. The 
solution was heated in a boiling water bath for 15 minutes, cooled and 
placed on a 1 x 7 cm Dowex-1 acetate column.to separate ALA pyrrole 
from aminoacetone pyrrole. ALA pyrrole was eluted from the Dowex 
column and quantitated as outlined by Marver et al. (94). 
The percent recovery of 50 nanomoles of ALA pyrrole (lower limit 
of detectability) added to the ion exchange column was 75± 5 percent. 
In thin layer and paper chromatography systems, the Rf of the standard 
ALA pyrrole was identical to the Rf of the Ehrlich reactii;ig substance 
from the Dowex column (Table I) .. Evidence of PBG formation was not 
detectable in the assay system.by the Ehrlich reagent. The activity 
of ALA synthetase was expressed as micromoles.of ALA produced/gram 
liver/hour. 
ALA Synthetase in Bone Marrow 
ALA synthetase activity was assayed in bone marrow from 12 por-
phyric, 14 normal nonporphyric and five anemic.nonporphyric cats. The 
enzyme activity in bone marrow cell mitochondria was determined by a 
modification of !:he method described by Bottomley and Smithee (11). The 
femora, tibiae, and humeri were taken from cats anesthetized with 
sodium pentobarbital. Each bone was split open and the marrow placed 
in 0.25 M sucrose containing 0.05 M phosphate buffer pH 7.4. A crude 
suspension of marrow was obtained by gently aspirating the marrQw five 
times through the hub of a 10 ml syringe. A bone marrow smear was made 
TABLE I 
CHROMATOGRAPHIC RESULTS OF EHRLICH POSITIVE SUBSTANCE ASSAYED 





Rf of Unknown 
Ehrlich Positive Substance 
0.90 
0.78 




*Paper chromatographic systems as described by Mauzerall and 
Granick (97). 
A: Upper phase of Butanol - Acetic Acid - H20 (4:1:5) solution. 
B: Upper phase of Butanol - l.SM aqueous ammonia (1:1) solution. 
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from the suspension.at this.time to determine the percent of erythroid 
cells. The marrow suspension was then further aspirated until all 
clumps were broken. The suspension was strained through.four layers of 
cheesecloth and brought to a final.volume of 15 ml with the 0.05 M 
phosphate buffered 0.25 Msucrose solution .. The number of nucleated 
cells in this suspension was determined in a leukocyte counting cham-
ber. The suspension was centrifuged at 750 x g for 15 minutes and, 
after removal of the supernant, the cells were resuspended in 10 ml of 
the phosphate buffered 0.25 M sucrose solution. A hemolysate was pre-
pared by sonificating the cells for 21 seconds using a Model W 140 
Sonifier Cell Disruptor set at position 8. Mitochondria were isolated 
by the method of Schneider.(128) modified by using 0.25 M sucrose-0.05 
M phosphate solution at pH 7.4 in place of 0.25 M sucrose. Mitochon-
drial protein concentrationwas determined by the method of Lowry et 
al. (90). 
ALA synthetase activity was measured in the mitochondria by the 
microassay method reported.by.Bottomley and.Smithee (11). ALA con-
centration was determined colorimetrically as the ALA pyrrole. Amino-
acetone which will.interfere with accurate measurement of the ALA 
pyrrole could not be detected in the assay by the solvent extraction 
technique employed by Granick (49). 
Sonification of the bone marrow cells was the only method tried 
which would produce complete lysis of all cells as determined by micro-
scopic examination of smears made from the sonificated preparation. 
Homogenization using a Ten Broeck homogenizer or treatment by rapid 
freeze-thawing did not adequately disrupt all the cells. The length 
of time and intensity at which the cells were sonif icated was critical 
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(Table II). Sonification at pQsition.8 for periods greater or less than 
21 seconds resulted.in a reduction in mitochondrial enzyme activity. 
ALA syuthetase activ.ity.was .. expressed both as picomoles of ALA 
produced/10 6 erythroid.cells/30 minutes and as picomoles ALA/10 6 nu-
cleated cells/30 minutes. 
ALA Dehydrase in Liver 
The activity of hepatic ALA dehydrase was determined in five por-
phyric and six nonporphyric cats. Two grams of liver (wet weight) were 
homogenized in a Ten Broeck homogenizer in 4 ml of cold 0.9 percent 
saline and strained through four layers of cheesecloth. ALA dehydrase 
activity was assayed by measuring the amount of PBG produced in a 0.25 
ml aliquot of ·the homogenate incubated under the conditions described 
by Gibson et al. (38). The activity of the enzyme was stopped by 
adding 10 ml of a TCA-HgC12 .mixture (80 ml of a 5 percent TCA plus 20 
ml of O.lM HgC12) and the precipitate removed.by centrifugation. PBG 
was estimated by adding 1 ml of a 4N.modifiedl Ehrlich's reagent to 1 
ml of the TCA supernate and determining the optical density at 553 mu 
after three minutes. Concentration of porphobilinogen was calculated 
using the extinction coefficient given by Granick and Mauzerall (51) 
and the enzyme activity expressed as micromoles of PBG produced/gram 
of liver/hour. Porphyrin formation, as determined by solvent extrac-
tion procedures, did not occur in the assay under the incubation con-
ditions used. 
1. 4N modified Ehrlich'.s .reagent was prepared daily by dissolving 
0.25 gm of paradimethylaminobenzaldehyde in 5 ml of .glacial acetic acid 
and adding 4 ml of 70.percent perchloric acid and 2.5 ml water. 
;. 
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TABLE II 
EFFECT OF SONIFICATION ON MARROW ALA 
SYNTHETASE ACTIVITY 
















*Identical aliquots of a marrow cell suspension were subjected 
to sonification at the intensity described in the method of assaying 
marrow ALA synthetase activity. 
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ALA Dehydrase in Erythrocytes 
The red cell ALA dehydrase activity was assayed in six nonpor-
phyric and six porphyric.cats •. A 10 ml.sampleof blood was collected 
in 0.66 ml of a 5 percent .hepa:t:in solution •. Erythrocytes .were collec-
ted by centrifugation at.1500 ·x-g for 10 minutes, washed.once and re-
constituted to their original volume with cold 0.9 percent saline. 
Complete lysis of .the cells was accomplished by freeze-thawing twice in 
an acetone-dry ice bath. 
ALA dehydrase activity.was determined by.measuring the amount 
of PBG produced in an incubation mixture composed of 1.75 ml of hemoly-
sate, 0.25 ml of a 0.119 M solution.of glutathione and 1 ml of a M/15 
phosphate buffer pH 7 .2 placed together in a Tht,mberg tube .. The reaction 
was started by the addition-of.0.2 ml of O.lM solution ot ALA from the 
side-arm of the Thunberg tube •. Incubation and.quantitation of PBG fol-
lowed the liver assay method except.that the reaction mixture was in-
cubated at 37° C. Enzyme activity was expressed as nanomoles of PBG/ml 
of packed red cells/hour. 
ALA Dehydrase in Bone Marrow 
The catalytic activity of ALA dehydrase in bone marrow was assayed 
in seven porphyric, seven nonporphyric, and three anemic nonporphyric 
cats. ALA dehydrase activity was determined in marrow hemolysate pre~ 
pared as described for the ALA synthetase marrow procedure. Nine-
tenths ml of hemolysate was added to 0.11 ml of 0.2 M glutathione solu-
tion pH 7.2 and 0.11 ml of 0.2.M phosphate buffer pH 7.2 in a Thunberg 
tube under nitrogen and.incubated.for one hour at 37° C for activation 
of the enzyme. At this time the.reaction was started by adding 0.066 ml 
of 0.1 MALA pH 7.2 from the side arm of the Thunberg tube and incubation 
was continued for an additional hour. It was found that vigorous 
mixing of the ALA with the incµbation media resulted in false low en-
zymatic activity. This was avoided by gentle addition and mixing of 
the substrate to the hemolysate. Enzyme activity was stopped by the 
addition of 1 ml of freshly prepared 0.15 M HgC12 in 7.5 percent TCA. 
The precipitate was removed by centrifugation at 5000 x g. One ml of 
the supernatant was added to 1 ml of 2 N modified Ehrlich's reagent. 
If a precipitate formed in the Ehrlich-TCA mixture, it was removed· 
by centrifugation and the optical density was determined at 553 mu 15 
minutes after addition of Ehrlich's reagent. PBG concentration was 
determined from a standard curve based on known concentrations of the 
monopyrrole. ALA dehydrase activity was expressed both as picomoles 
6 of PBG produced/10 total nucleated cells/hour. 
A small amount of URO was detected in the TCA supernatant by 
spectrophotometric examinati.on at 406 mu. The amount of URO produced 
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during the incubation was approximately 12 percent of the PBG produced. 
Ferrochelatase in Bone Marrow 
Ferrochelatase activity was measured in hemolysates of bone marrow 
prepared from 18 animals and in mitochondria isolated from bone marrow 
cells of 17 animals. Both methods were based on procedures reported 
by Bottomley (10). 
Ferrochelatase in Bone Marrow Hemolysate. Ferrochelatase activity 
was assayed by the hemolysate method in five porphyric, 10 normal non-
porphyric and three anemic nonporphyric cats. The hemolysate was pr<t-· 
pared as discussed in the method for measuring bone marrow ALA synthe-
tase activity. The incubation mixture for determination of ferrochela-
tase activity was prepared by adding 1.0 ml of hemolysate to a Thunberg 
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tube which contained 0.25 ml of 4.3 x io-4 M ferrous-59 citrate1 (spe-
cific activity of 1 microcurie/3 micrograms of Fe++). After preincuba-
tion under nitrogen for two minutes at 37° C, 0.25 ml of 1.42 x 10"'"4 M 
protoporphyrin IX was added.to.the incubation mixture from the side-arm 
and the incubation continued for 10 minutes. The reaction was stopped 
by adding 20 ml of a solution composed of one part 2: percent strontium 
chloride hexahydrate in glacial acetic acid and three parts acetone. 
Carrier heme was provided by the addition of 2 ml of hemoglobin solu-
tion (10 ml of packed red cells plus 5 ml of water) to the mixture. 
Heme was crystallized by the method of Labbe and Nishida (82). The 
crystals were dried, weighed and solubilized in 0.5 ml of pyridine, 
after which the specific radioactivity was determined using a Model 
810 Baird Atomic Scintillation detector equipped with a Baird Atomic 
Model 132 Multiscaler II and Model 960R Timer. The counting efficiency 
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of the instrument for Fe was 28 percent. Hemoglobin conceritration 
was determined in the hemolysate and in the carrier hemoglobin solution 
by the cyanomethemoglobin method (156). 
PROTO IX was prepared from PROTO IX dimethyl ester. The ester was 
recrystallized in chloroform~methanol solution, dried, then hydrolyzed 
to free PROTO with 7.5 N HCl. PROTO IX was precipitated as the sodium 
salt by slowly adding 7.5 N NaOH until the acid solution was neutralized. 
The precipitate was collected by centrifugation, washed twice with 1. per-
cent acetic acid, and twice with deionized water then stored in a dessi-
cator. A solution of protoporphyrin IX was freshly prepared for each 
assay as described by Bottomley (10). The labelled iron solution was 
++ 1. Ferrous-59 citrate (specific activity of 5 to 200 ucuries/ug 
Fe ) was purchased from Abbott Radio-Pharmaceuticals. 
48 
prepared by diluting ferrous-59.citrate with ferrous ammonium sulfate 
until a specific activity of.! microcurie/3 micrograms of Fe++ was 
obtained. The ferrous ammonium sulfate was freshly made for each assay 
in .25 M sucrose in 0.05.M.phosphate pH 7.4. 
The assay for.ferrochelatase did not detect enzyme activity in 0.1 
ml or less of hemolysate (approximately 2.0 mg of protein). However, 
the velocity of the reaction was proportional to the concentration of 
enzyme when amounts of hemolysate in excess of 0.1 ml were used (Fig-
ure 2). Enzymatic activity was determined from the slope of a line 
obtained by graphing the velocity of four different enzyme dilutions, 
usually 0.3, 0.5, 0.7, 0.9 ml of hemolysate. Ferrochelatase activity 
was expressed both as picomoles.of heme produced/106 erythroid cells/10 
minutes and picomoles of heme produced/106 nucleated cells/10 minutes. 
PROTO concentrations above 0.71 x l0-4M in the incubation 
mixture markedly inhibited ferrochelatase activity (Figure 3). 
Ferrochelatasein.Bone Marrow Mitochondria. Ferrochelatase acti-
vity was determined by the mitochondrial method in seven porphyric, 
eight normal nonporphyric, and two nonporphyric anemic cats. Mito-
chondria were prepared in the same manner as described in the marrow ALA 
synthetase method. Ferrochelatase was solubilized by the addition of 
0.2 ml of 11 percent sodium cholate to 2.0 ml of mitochondrial sus-
pension (10 mg protein/ml) and the mixture slowly stirred with 
a magnetic mixer for 30 minutes at 4°C. 
The incubation.mixture was prepared by adding 0.9 ml of the 
solubilized mitochondrial solution to a Thunberg tube which contained 
0.1 ml of 2.6 x 10-2M L-ascorbic acid pH 7.4 and 0.25 ml of 4.3x10-4M 
ferrous 59Fe (specific activity of 1 microcurie/3 micrograms of Fe++). 
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The Thunberg tube was evacuated, flushed with nitrogen and preincubated 
as described in the hemolysate method. After preincubation, the re~ 
-4 
action was started by adding 0. 25 ml of 3. 60 x 10 M protoporphyrin 
from the side arm. The subsequent procedure was the same as that for 
the hemolysate assay. 
Ascorbic acid at the concentration used in the assay and treatment 
of the mitochondria with sodium chelate was required for maximal ferro-
chelatase activity (106,71). PROTO concentrations at levels which in-
hibited ferrochelatase in the hemolysate preparations did not affect 
the activity of the enzyme in the mitochondrial assay procedure. How-
ever, the mitochondrial assay was similar to the hemolysate method in 
that the graph of velocity versus mitochondrial suspension did not go 
through the intercept (Figure 2). Measurement of ferrochelatase acti-
vity was accomplished by the same procedure as in the hemolysate method. 
6 The enzyme activity-was -expressed both as picomoles of heme/10 




Porphyrins and Porphyrin Precursors 
Urinary Porphyrins and Porphyrin Precursors 
Average daily concentrations of porphyrins and porphyrin precursors 
and their ranges in urine collected over a four-day period for each of 
five normal and five porphyric cats are graphically illustrated in 
Figure 4. Daily levels for each animal are given in the Appendix 
Table XIV. 
No significant difference in the concentration of urinary ALA was 
noted between normal and porphyric cats. The amount of ALA excreted 
by individuals in both groups of cats varied greatly from day to day. 
During the four day collection period, the widest variation in daily 
urinary ALA levels in the same in.dividual of the nonporphyric ·group 
ranged from a low of 108 to a high of 1,727 micrograms/24 hours, while 
in the porphyric group, the greatest range in an individual animal was 
from 77 to 480 micrograms/24 hours. The range of ALA excretion values 
among the five ncmporphyric cats was 22 to 1741 micrograms/24 hours 
with a range of the mean for each animal during the four-day period of 
103 to 961 micrograms and an overall mean for the five cats of 338 
micrograms/24 hours. The range ifi daily excretion values of ALA among 
the five porphyric cats was 77 to 535 micrograms/24 hours with 
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Figure 4. Urinary Levels of P,orphyrins and.P.orphyrin Precursors for Five Normal and Five P.orphyric Cats. 
V1 
tod 
an overall mean for the five cats of 338 micrograms. 
In contrast to ALA excretion, the urinary excretion of PBG was 
markedly increased in the porphyric cats. The overall mean value for 
the five porphyric animals during the.five-day period was 729 micro-
grams/24 hours compared to a mean of 162 micrograms/24 hours for 
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the five nonporphyric cats. The daily excretion of PBG in the porphyric 
cats ranged from 102 to 2128 micrograms/24 hours and the range in non-
affec ted cats was 0 to 535 micrograms/24 hours. The excretion levels 
of PBG fluctuated widely among the individual animals of both the por-
phyric and nonporphyric group over the four day collection period. 
The urinary excretion of URO and COPRO was much higher in the 
porphyric than in the nonporphyric cats with URO being much higher than 
COPRO levels in the porphyric group. The average 24-hour excretion 
levels of URO and COPRO for the five porphyric cats during the four-day 
collection period were 213 and 55 micrograms, respectively, with a 
range of 80 to 626 micrograms of URO and 15 to 124 micrograms of COPRO. 
Corresponding 24-hour excretion values for nonporphyric cats were 
8.2 micrograms of URO and 8.4 micrograms of COPRO, with a range of one 
to 22 micrograms for each porphyrin. 
There was a direct correlation between the urinary levels of por-
phyrins and PBG in the porphyric cats (Figure 4). The two porphyric 
cats with the highest urinary.excretion levels of porphyrins also 
excreted the highest amounts.of PBG. Similarly, the porphyric cat with 
the lowest level of PBG also.excreted the least amount of porphyrins. 
The highest urinary porphyrin levels were roughly four fold greater 
than the smallest amount while the highest PBG levels were approxi-
mately three fold that of the smallest PBG level. Much of the daily 
54 
variation in levels.of porphyrins and porphyrin precursors may have re-
sulted in part from the day to day variation in urine volume during the 
four day collection period. 
Red Cell Porphyrins 
Concentrations of URO, COPRO and PROTO were determined in erythro-
cytes from peripheral blood.from four porphyric and three nonporphyric 
cats. The values for each of these porphyrins in each animal are given 
in Table III. Red cell PROTO levels were much higher than either the 
COPRO or URO levels in both the nonporphyric and porphyric cat groups; 
however, PROTO and COPRO in porphyric erythrocytes were greatly ele-
vated above the levels found in nonporphyric red cells. 
i'The range of values in the nonporphyric animals was 4 to 30 micro-
grams/100 ml red cells for PROTO and 0 to 1 micrograms for COPRO. The 
range of values in the porphyric animals. was 152 to 349 micrograms/100 
ml of red cells for PROTO.and-13 to 59 micrograms/100 ml of red cells 
for COPRO with means of 249 and.28 micrograms respectively. 
A moderate increase in URO.concentration was found in erythrocytes 
from the porphyric cats. The mean value for URO in porphyric erythro-
cytes was 6.5 micrograms/100 ml.red cells compared to the mean of 2.7 
micrograms/100 ml of red cells in the nonporphyric animals. 
The distribution of types I and III isomers of COPRO was determined 
in the erythrocytes from one grade 1 porphyric cat and in the urine 
from one grade 4 porphyric cat. The type I COPRO isomer predominated in 
both the red cells and urine of these individuals. The I isomer repre-
sented 93 percent of the urinary COPRO and 66 percent of the erythrocyte 
COPRO. Isomer distribution was not determined in erythrocytes and urine 




CATS CO PRO URO PROTO 
yg/100 ml RBC 
Porphyric 
53 (grade 2) 21.5 o.o 330.0 
353 (grade 2) 12.9 7.0 349.0 
63 (grade 2) 18.4 4.0 152.0 
71 (grade 1) 59.0 11.0 165.0 
MEAN 28.0 6.5 249.0 
Nopporphyric 
45 0.0 3.6 4.3 
354 1.1 3.0 30.0 
223 1.0 1.6 14.6 
MEAN 0.7 2.7 14.6 
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Enzyme Studies 
ALA Synthetase Activity.in.Liver and Bone Marrow 
Table V summarizes the hepatic ALA synthetase activity obtained 
from three porphyric and.eight.nonporphyric cats. Individual values for 
ALA synthetase activity are given in Appendix Table XV_I_, No significant 
difference was noted between the two groups (p>0.10) although the enzyme 
activity for one porphyric cat was low in comparison to activities in 
the normal cats. The range of hepatic ALA synthetase activities in the 
nonporphyric cats was 4.3 to 12.5 nanomoles of ALA produced/hour/gm of 
liver and the range in the porphyric cats was 2.0 to 9.8 nanomoles of 
ALA/hour/gm of liver. 
Bone marrow ALA synthetase activity was determined in 14 nonpor- . 
phyric and 12 porphyric cats. Activity of the enzyme was expressed both 
as picomoles of ALA/106 nucleated cells/30 minutes and picomoles/106 
erythroid cells/30 minutes. Mean ALA synthetase activity in marrow 
from porphyric cats by both methods of calculation was higher than that 
in marrow from porphyric cats (Table VII). Enzyme activity for non-
porphyric cats ranged from 15 to 73 picomoles of ALA produced/30 
minutes/106 erythroid cells with a mean value of 39 picomoles. In 
comparison, the range found in porphyric cats was 24 to 173 picomoles/30 
minutes/106 erythroid cells with a mean value of 73.4 picomoles. 
No correlation was found between ALA synthetase activity and 
severity of the porphyric condition. The markedly porphyric grade 3 
cats had ALA synthetase activities similar to the mildly porphyric 
grade 1 cats (Appendix Table V ). No significant difference in the 
levels of bone marrow ALA synthetase activity was noted between nonpor-
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TABLE VI 
BONE MARROW ALA DEHYDRASE ACTIVITY 
pmoles PBG/hour 
GROUP 
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S.E. = 0.93 
13. 7 
6.2-20.8 
S.E. = 25.5 
p<0.005 
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basis of mitochondrial protein (Appendix Table :X.VII) .. :':!,ALA_ synthetase 
activity was also determined in bone marrow of five anemic nonporphyric 
cats. The values obtained in this group are given in Table VIII. The 
6 
activity of ALA synthetase when calculated on the basis of 10 nucleated 
cells was considerably elevated above values found in porphyric as well 
as the nonanemic nonporphyric cats; however, the enzymatic activity 
' 6 
calculated on the basis of 10 erythroid cells was near the mean of 
porphyric marrow ALA synthetase activity. ALA synthetase activities 
per mg of mitochondrial protein in the anemic nonporphyric cats were 
similar to those in the porphyric and normal groups. 
ALA Dehydrase Activity in Liver, Red Cells and Bone Marrow 
Hepatic ALA dehydrase activity was determined in five porphyric 
and six nonporphyric cats. The results of these determinations are sum-
marized in Table IV and the complete data is given in Appendix Table XV. 
No significant difference in hepatic ALA dehydrase activity was found 
between the two groups (P>0.10). 
ALA dehydrase activity was determined in the red cells of six 
porphyric and six nonporphyric cats. The enzymatic activity in porphyric 
erythrocytes ranged from 225 to 640 nanomoles of PBG/ml red cells/hour 
with a mean value of 374 nanomoles. The activity in nonporphyric 
erythrocytes ranged from 61 to 201 nahomoles of PBG/ml red cells/hour 
with a mean value of 145 nanomoles. The difference in red cell ALA de-
hydrase activity between the two groups was significant at p<0.01 level. 
The highest ALA dehydrase levels found in erythrocytes occurred in those 
from the porphyric cat which had the highest reticulocyte count (4.8 
percent reticulocytes); however, there was no direct correlation between 
erythrocyte enzyme levels in cats with lower but slightly elevated 
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TABLE VIII 












106 Erythroid Cells 
1171 .emoles ALA/30 min. 
51-92 
1519 Emoles PBG/hr. 
t740-26S2 
66 Emoles Heme/10 min. 
59-74 
22-52 
*Numbers of cats in the enzyme study. 
1'[Mean. 
tRange. 
10 6 Nucleated Cells 
19 pmoles ALA/30 min. 
- 7-27 
357 Emoles PBG/hr. 
104-536 




reticulocyte values (Table IX). 
Bone marrow ALA dehydrase activity was determined in seven porphyric 
and seven nonanemic nonporphyric cats in which marrow ALA synthetase and 
ferrochelatase determinations were also made. The mean ALA dehydrase 
6 
activity per 10 erythroid cells for porphyric cats was 1.8 fold greater 
than that for nonporphyric cats. A range of 1098 to 4414 picomoles of 
PBG/106 erythroid cells/hour was found in porphyric cats compared to a 
6 
range of 882 to 1544 picomoles of PBG/10 erythroid cells/hour for non-
porphyric cats. However, since only one of the porphyric cats had 
marrow dehydrase levels markedly higher than those from the nonporphyric 
group, the difference between the two groups was not statistically sig-
nificant (P>0.10). 
In addition to the seven nonanemic nonporphyric cats in the pre-
ceding group, marrow ALA dehydrase activity was also determined in three 
anemic nonporphyric cats used in the other marrow enzyme studies. In 
these anemic animals, ALA dehydrase activity, when calculated on the 
basis of 106 nucleated cells, was markedly elevated, but when the calcu-
6 
1ations were based on 10 erythroid cells, the enzymatic activity was 
comparable to normal and porphyric values (Table VIII). 
Ferrochelatase Activity in Bone Marrow 
A total of 18 nonanemic nonporphyric, five anemic nonporphyric, 
and 12 porphyric cats were used in the studies of bone marrow ferro-
chelatase. Many of these animals were also represented among those used 
in marrow ALA synthetase and dehydrase studies. The hemolysate assay 
method was used for marrow from a total of 18 cats and the mitochondrial 
method on 17. Marrow from porphyric cats, as well as from nonanemic non-
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activity in marrow was similar among all three groups of cats by each 
of the two methods used and also similar when the activity measured by 
either method was expressed on the basis of 106 erythroid and 106 
nucleated cells (Tables X, XI). 
Values of ferrochelatase activity in marrow from porphyric cats, 
as determined by the mitochondrial method, ranged from 19 to 93 pico-
moles heme/106 erythroid cells/10 minutes with a mean value of 38.5. 
The range of ferrochelatase activities in the nonporphyric cats was 
8.4 to 70.6 picomoles/106 erythroid cells/10 minutes with a mean value 
of 31.3 picomoles. Similar values were present in marrow from the 
anemic nonporphyric cats. 
Although differences were apparent among the different grades of 
porphyric cats in which marrow was assayed by the hemolysate method, no 
significant differences were present among different grades of porphyric 
cats in which marrow was assayed by the mitochondrial method. Since it 
was noted that increased amounts of PROTO had an inhibitory effect on 
ferrochelatase activity in hemolysate preparations, the presence of 
higher levels of endogenous PROTO in the more porphyric cat marrows 
possibly explains the differences noted between the two assay methods. 
Ratio of Bone Marrow Enzymatic Activities 
A comparison of the ratios of mean activities of ALA synthetase, 
ALA dehydrase, and ferrochelatase in bone marrow from nonanemic non-
porphyric, anemic nonporphyric, and porphyric cats are given in Table 
XII. ALA synthetase/ferrochelatase and ALA dehydrase/ferrochelatase 
ratios for the nonanemic nonporphyric cats were 1.24 and 21.4 respec-
tively, in comparison to ratios of 1.90 and 48.1 for porphyric cats. 
The ratio of ALA synthetase/ferrochelatase and of ALA dehydrase/ 
ferrochelatase in marrow from the anemic nonporphyric cats was 1.92 and 
TABLE X 
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31.3 t 
13.3-70.6§ 
S.E. = 6.95* 
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p<O. 50 
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p<0.40 
Number of animals in group. 




. 1 . 
' BONE MARROW HEMOLYSATE FERROCHELATASE ACTIVITY 
~---~~------~--~--------------------------------~ pmoles Heme/10 minutes 
GROUP 
10 6 Erythroid Celis 10 6 Nucleated Cells 
65.7t 10.5 
NORMAL 13. 0-164. 0§ 1. 5-28. 0 
(10) S.E. = 16.8* S.E. = 2.47 
58.2 11.0 
PORPHYRIC ll.5-144.0 3. 3-21. 6 
(.5) S.E. = 24.1 S .E. = 3.6 
p<eO. 50 p<O. 50 
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TABLE XII 
RATIO OF ENZYME ACTIVITY IN BONE MARROW 
(Based on 106 Erythroid Cells) 
Nonporphyric 
ENZYME RATIO Nonanemic 
ALA Si:!J:thetase 
1.24 Ferrochelatase (mit.)~ 
ALA Si:!J:thetase 
0.59 Ferrochelatase (hem.)* 
ALA SEthetase 
0.036 ALA Dehydrase 
ALA Deh:y;drase 31.4 Ferrochelatin (mit.) 
'ALA Dehxdrase 


















41.l respectively, closely approximating those for the porphyric group. 
The ratio of ALA synthetase/ALA dehydrase was similar for the porphyric 
and '.anemic nonporphyric and nonanemic nonporphyric cat groups. 
Hematology 
The various hematologic parameters, as well as percent of marrow 
erythroid cells, for all cats used in the marrow enzyme studies are sum-
marized in Appendix Table XIII. The hematologic and erythroid cell 
values were determined on speqimens obtained at the time the animals 
were killed. The mean percent erythroid cells for porphyric cats was 
21.6 while that for the anemic nonporphyric cats was 25.9 and was 18.4 
for the nonporphyric cat group. The difference in percent of ery~h­
roid cells between the porphyric and the nonanemic nonporphyric groups 
was not statistically significant (P>0.10). Data from the anemic non-
porphyric cats was not compared.statistically with that of the other 
groups due to small numbers of animals in the group. Many of the por-
phyric cats used in the studies had mild anemia. The range of hemo-
globin concentrations in the porphyric group was 8.7 to 15.3 gm per 100 
ml of blood. 
CHAPTER V 
DISCUSSION AND CONCLUSIONS 
Tobias (140), in his report of the first cases of feline porphyria, 
mentioned the presence of excess PBG, as well as URO and COPRO, in urine 
obtained from one of the two porphyric cats described in the report. 
The reported presence of an excessive amount of PBG in the urine of this 
cat was significant since other features of feline porphyria described 
in the report more nearly corresponded to congenital erythropoietic 
porphyria (CEP) in man and cattle but excessive urinary excretion of 
PBG is not found in CEP of either of the latter species (16,151,149). 
Also the reported presence of urinary PBG could be questioned because 
the tests were of qualitative nature and it has been well established 
that false positive tests for PBG occur with Ehrlich's reagent unless 
special precautions are taken (27). The findings in the initial phase 
of the present investigation confirmed the presence of large amounts 
of PBG and URO and COPRO as characteristic features of feline por-
phyria. This finding showed that feline porphyria is unique among the 
known porphyric diseases of man and animals in certain of its features 
since excessive production of PBG had been previously observed only in 
the hepatic porphyrias of man, none of which are characterized 
by porphyrin pigmentation of teeth and bone (124). The latter feature 
has been observed only in CEP of man and animals. 
The excessive production of PBG by the porphyric cat raised the 
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question of whether the disease in this species is merely a unique 
form of CEP or if the defect involved both erythropoietic and non-
erythropoietic tissues. The nonerythropoietic (hepatic) porphyrias of 
man are characterized by urinary excretion of excessive amounts of ALA 
as well as PBG and, at certain times,.elevated levels of fecal and 
urinary porphyrins which are primarily of the III isomer type (141,46, 
124), Erythrocyte porphyrin levels are normal in the hepatic porphyrias 
of man (124). Urinary ALA levels were found to be normal in feline 
porphyria and the erythrocytes contained high concentrations of URO, 
COPRO and PROTO. In the present studies, the majority of COPRO ex-
tracted from urine and from erythrocytes of each of two separate por-
phyric cats was found in both instances to be predominantly of 
the I isomer type. Concurrent studies conducted by Glenn (39) with 
the same colony of porphyric cats have further shown. that the primary 
isomer of both URO and COPRO in urine, feces and red cells is of the 
type I series. 
An additional feature of feline porphyria which differs from 
hepatic porphyrias and CEP of man is the presence of large amounts of 
PROTO in the erythrocytes of porphyric cats. High erythrocyte PROTO 
levels is the primary feature of erythropoietic protoporphyria (EP) in 
man (91,109) but is also a prominent feature in CEP of cattle (151,16). 
Thus, feline porphyria has features which overlap the two types of 
erythropoietic porphyria of man and CEP of cattle and swine, as well 
as certain features of the hepatic porphyrias of man. However, since 
overproduction of the type I porphyrin isomers, porphyrin pigmentation 
of teeth and bones, and elevated erythrocyte porphyrins are features 
of CEP in man, cattle and swine and elevated erythrocyte PROTO levels 
are a prominent feature in cattle, it would appear that the features 
of feline porphyria are more compatible with CEP and that excess 
urinary excretion of PBG in feline porphyria is a manifestation of an 
unique defect in the porphyric cat. 
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The purpose of the enzyme studies in this investigation was to 
determine whether or not defective heme biosynthesis in feline porphyria 
involved tissues other than the erythropoietic tissues and to provide 
more specific information regarding the site(s) of the defect(s) in the 
heme biosynthesis pathway responsible for porphyria in the feline. 
It has been demonstrated that hepatic ALA synthetase activity is 
greatly increased in patients suffering from acute intermittent por-
phyria (AIP), porphyria variegata (PV), and hereditary coproporphyria 
(HC) (142,98,76,139). The activity of ALA dehydrase also tended to 
increase but not to the magnitude exhibited by ALA synthetase (142). 
Such increases were probably responsible for the elevated urinary levels 
of ALA and PB9 found in these patients. In addition, Strand et al. 
(139) have demonstrated a decrease in the utilization of PBG by hepatic 
tissue from cases of AIP. ON the basis of this finding, they suggested 
that AIP is due to a partial deficiency of UROgen I synthetase. Since 
heme acts as a repressor for ALA synthetase production, a partial block 
at the UROgen I synthetase level in the heme biosynthesis pathway would 
result in decreased heme production thus leading to increased synthesis 
of ALA synthetase (49). 
Kaufman and Marver (76) have suggested that HC and PV also may 
result from partial enzymatic deficiencies but not at the same site 
in the heme biosynthesis pathway. 
The excessive urinary excretion of PBG by the porphyric cat 
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suggests the possibility that defective mechanisms in the heme biosyn-
thesis pathway similar to those involved in hepatic porphyrias of man 
may be involved in feline porphyria. However, results of the enzyme 
assays in hepatic tissue from porphyric cats gave no indication of an 
increase in catalytic activity of ALA synthetase or ALA dehydrase. 
Mcintyre et al. (98) have reported that hepatic ALA synthetase activity 
in RC patients was elevated only during acute attacks of the disease. 
It is possible that a similar situation may exist in feline porphyria 
and that normal values of ALA synthetase activity found in affected 
cats may reflect a state of remission of the disease at the time of 
assay. However, the activity of ALA synthetase is markedly elevated 
during periods of remission of AIP and in PV and further increases 
during acute attacks (139). Therefore, the negative findings of the 
enzyme studies in hepatic tissue of the porphyric cat suggest that the 
liver probably ~oes not contribute significantly to the abnormal PBG 
and porphyrin production. 
Enzyme studies concerning the erythropoietic porphyrias have been 
much more limited than in the hepatic porphyrias. Levin and coworkers 
(118,84,117) have recently shown that the activity of UROgen III co-
synthetase is greatly reduced in erythrocyte hemolysates from man and 
cattle with CEP. Levin and Flyger (85) have also demonstrated a 
deficiency of this enzyme in the physiologic porphyria of the fox 
squirrel. In contrast, Levin and Glenn (86) found that the activity 
of UROgen III cosynthetase was not deficient in red cell hemolysates 
from porphyric cats. 
Evidence that defective porphyrin synthesis occurs in erythroid 
tissue of the porphyric cat is provided by the presence of large 
amounts of porphyrins in erythrocytes •. Further indication that a 
metabolic defect is present in erythropoietic tissue is provided by 
concurrent investigations by Glenn et al. (42), who demonstrated the 
presence of fluorescent erythroid cells in bone marrow and peripheral 
blood of porphyric cats. 
The excess production of PBG, type I isomers of URO and COPRO, 
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and the presence of large amounts of PROTO in the red cells suggests 
several sites of possible enzyme defects in heme biosynthesis which 
could be involved in feline porphyria. Levin and Glenn's demonstration 
that UROgen III cosynthetase activity is not deficient in red cells 
from porphyric cats would appear to rule out a decrease in the activity 
of this enzyme as being involved. Other likely sites of the enzyme 
defect(s) are ALA synthetase, ALA dehydrase and ferrochelatase. Because 
of the particular biochemical features in feline porphyria, it was felt 
that the present investigation should include studies of all three 
enzymes. 
ALA dehydrase activity was found to be increased in circulating 
red cells from porphyric cats. However, the cause and significance 
of the increase is difficult to assess due to the elevated reticulo-
cyte counts in the circulating blood of the porphyric cats. It is well 
known that reticulocytes and young nonreticulated"red cells normally 
have higher concentrations.of various enzymes than older red 
cells; therefore, much of the increase in ALA dehydrase activity could 
be a reflection only of the increased numbers of young red cells in 
porphyric cat blood. Since the bone marrow is populated primarily by 
immature erythroid cells, it .. was _.felt -that this tissue would likely pro-
vide a more standard basis for determining ALA dehydrase activity and, 
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because of the mitochondrial location of ALA synthetase and ferrochela~ 
tase, would allow assays for all three enzymes in the same tissue 
for comparative purposes. Further assays of these enzymes were there~ 
fore conducted in bone marrow. 
The enzymatic activities of ALA synthetase, ALA dehydrase and 
6 ferrochelatase were caiculated both on the basis of 10 erythroid cells 
and 106 total ,nucleated cells. 6 Enzymatic activity based on 10 total 
nucleated cells takes into account the activity of the enzymes involved 
in non-hemoglobin heme synthesis by myeloid cells as well as enzymatic 
activity in erythroid cells. However, since the present studies were 
primarily concerned with localization of the defect in heme biosynthesis 
in erythropoietic tissue, it would seem that enzymatic activity expres-
sed on the basis of erythroid cells is more appropriate, especially 
since it is assumed that the erythroid cells are the primary source 
of enzymes involved in heme biosynthesis in the .bone marrow (11). 
Enzymatic activity based on total nucleated cells does not take into 
account the myeloid-erythroid ratio and therefore tends to give a 
higher value in marrow specimens which have significantly higher per-
centages of erythroid cells. This was shown to be the case with the 
anemic,nonparphyric cats which had much higher erythroid cell percen-
tage than either the porphyric or normal cats. When enzymatic activities 
for the anemic cats were expressed on the basis of total nucleated cells, 
the values were much.higher. Expression of the data on the basis of 
106 erythroid cells provides a more standard basis for comparison of 
the anemic, porphyric and normal cats. 
Bone marrow ALA synthetase.activity in porphyric cats was signi-
ficantly elevated above the levels present in nonanemic nonporphyric 
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animals, but there was no apparent correlation between ALA synthetase 
activity and the severity of porphyric condition. There was a con-
siderable range of values among the entire group of porphyric animals 
as well as among the animals of each porphyric grade group. Differences 
in age among the porphyric cats could be one of the factors which might 
explain the wide range of values in the different porphyric grade 
groups as well as in the nonporphyric cats. Other possible explanations 
for the wide variation of ALA synthetase activity among both porphyric 
and normal cats could be differences in levels of such physiological 
factors as certain of the sex steroid. hormo~es or their metabolites and 
erythropoietin. It has been shown that certain steroids and their 
metabolites, particularly those of the 5S-H configuration, induce pro-
duction of ALA synthetase in hepatic and erythroid tissues (48,74). 
It has also been shown th~t erythropoietin enhances ALA synthetase 
activity in rabbit cell cultures (11). ALA synthetase induction by 
erythropoietin is suggested by results obtained from the anemic non-
porphyric cats. These cats had elevated ALA synthetase activities com-
parable to the mean ALA synthetase activity of the porphyric cat. ALA 
dehydrase activity in bone marrow from some of the porphyric cats was 
elevated to various degrees. The mean of the activities among the por-
phyric cats was 1.8 fold greater than the mean activity of the nonanemic 
nonporphyric cats; however, this difference was not.statistically sig-
nificant due to the degree of overlap among the porphyric and nonpor-
phyric groups and the wide ranges within each group. The anemic 
nonporphyric cats showed elevations similar to those in the porphyric 
group. The level of enzyme activity.in the individual animals of all 
three groups was generally in direct proportion to the level of ALA 
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synthetase activity •. As was the case with ALA synthetase, there was 
no correlation between ALA dehydrase activity and the degree of porphyria. 
Ferrochelatase activity in bone marrow hemolysates and in mito-
chondria isolated from bone marrow.cells in general was similar for 
porphyric, nonanemic nonporphyric, and the anemic nonporphyric groups. 
However, since ALA synthetase was elevated in the porphyric cats, the 
ALA synthetase/ferrochelatase ratio was greater in the porphyric group. 
During validation of the ferrochelatase procedure, it was found that 
activity of the enzyme in hemolysates was inhibited by concentrations 
-5 of PROTO IX greater than 7.1 x 10 Mand it was later noted that the 
two most severely affected porphyric cats showed ferrochelatase 
activities at the lower range limit for the nonporphyric cats. The 
tendency of hemolrsates from grade 3 porphyric cats to have low 
ferrochelatase activities probably was a result of the presence of large 
amounts of endogenous PROTO. Mitochondrial ferrochelatase activity 
was not affected by PROTO concentrations which were inhibitory to the 
enzyme in the hemolysate assay. No .difference in mitochondrial fer-
rochelatase activity was noted among any of the cats, regardless of 
the severity of the porphyric condition. 
Whether or not ferrochelatase is .. inhibited in vivo by PROTO which 
accumulates in the feline porphyric erythrocyte is not known. If 
excess PROTO is inhibitory to ferrochelatase in vivo, the excess PROTO 
which accumulates initially as a result of a metabolic defect would 
favor further PROTO accumulation because of its inhibitory effect on 
ferrochelatase activity. The elevated ALA synthetase activity con-
current with the normal ferrochelatase activity present in pqrphyric 
cat bone marrow may contribute to PROTO accumulation by causing 
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biosynthesis of more PROTO than can be effectively.catalized to heme by 
ferrochelatase. However, the marked excess accumulation of PROTO in 
the red cell of the porphyric cat could occur in a manner similar to 
that suggested by Goldberg .and Rimington.-(46) to explain the excess 
erythrocyte PROTO levels.in.bovine porphyria without involving a sub-
strate overload of ferrochelatase. They noted that red cell hemolysates 
from nonporphyric cattle formed much more PROTO from porphyrin pre-
cursors than did hemolysates from nonporphyric humans. They concluded 
that mitochondria are retained in maturing bovine red cells longer than 
in human red cells and that this species difference accounted for the 
PROTO found in CEP of cattle and not in man. The feline erythrocyte 
may be similar in this respect to the bovine red cell and the PROTO 
accumulation may be only indirectly related to the metabolic defect 
responsible for feline porphyria. In any case, the results df this 
study indicated that the elevated PROTO levels in porphyric feline 
red cells were not caused by a ferrochelatase deficiency since in 
the mitochondrial f errochelatase assay method there was no indication of 
a difference in enzyme activity between the porphyric and.nonporphyric 
cats. 
The only positive indication in the present investigations of a 
possible site of the defect in feline porphyria is the finding of in-
creased ALA synthetase activity in bone marrow. However, a number of 
possibilities should be explored in considerations regarding sites in 
the pathway and mechanisms which may be involved in the defective por-
phyrin metabolism responsible for the abnormal production of porphyrins 
and porphyrin precursors observed in feline porphyria. The excessive 
production of the type I.isomer.of porphyrins which occurs in the 
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porphyric cat must be due to an imbalance between the catalytic activi-
ties of UROgen I synthetase and UROgen III cosynthetase such that the 
level of activity of UROgen I,synthetase is much greater than that 
of UROgen III cosynthetase. -This -type of imbalance could occur if the 
activity of UROgen III cosynthetase-is decreased without a concurrent 
decrease in UROgen I synthetase activity or if the activity of UROgen 
I synthetase is elevated in absence of an elevation in UROgen III co-
synthetase. Levin and Glenn (27) found that the activity of UROgen 
III cosynthetase is not decreased in red cells of the porphyric cat, 
thus the abnormal production of the I isomer of URO and COPRO 
would appear to result from an increased activity of UROgen I synthe-
tase that exceeds the catalytic capacity of UROgen III cosynthetase. 
However, overproduction of UROgen I synthetase, in itself, would have 
little effect on porphyrin metabolism, since accelerated activity at 
this step in heme biosynthesis is dependent upon the availability of 
the substrate, PBG. It would appear, therefore, that the metabolic 
defect responsible for the elevations-of porphyrins primarily of 
the I isomer type centers around the mechanism(s) involved in the 
excessive PBG production. 
PBG levels may increase as a result of either a decrease in its 
utilization by UROgen I synthetase, the only known enzyme that uses PBG 
as a substrate, or by an increase in its rate of synthesis by ALA de-
hydrase. Since the type I isomer of porphyrins is produced in con-
siderable excess in feline porphyria and since Levin and Glenn have 
shown that UROgen III cosynthetase is not deficient, UROgen I synthetase 
activity cannot be decreased. Therefore the high levels of PBG must 
be the result of an increased rate of synthesis.of PBG. ALA dehydrase, 
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which catalyzes the formation of PBG from two molecules of ALA, does 
not appear to control the rate.of PBG production in porphyric and normal 
cats or in hepatic tissue from.other animals or man unless, as sug-
gested by two reports,. heme acts as a .negative feedback repressor on 
this enzyme (13,19). Overactivity of.ALA dehydrase might occur if a 
structural abnormality exists in the enzyme which prevents inhibition 
by heme if feedback inhibition operates in the erythroid cell. How-
ever, the very high levels of ALA dehydra~e in relation to the levels 
of ALA synthetase, as indicated by the results of this investigation, 
suggest that ALA synthetase activity controls the rate of PBG produc-
tion by limiting the amounts of ALA available for use as a substrate 
by ALA dehydrase. Therefore, the elevated levels of PBG and porphyrins 
in feline porphyria would seem to originate by ALA synthetase over-
activity. 
The elevated bone marrow ALA synthetase activity in porphyric cats 
would explain the porphyric condition if the elevation were of suf-
ficient magnitude to overload UROgen.III cosynthetase. The mean in-
creased levels of ALA synthetase activity in porphyric cats was twice 
that found in normal cats. This represents a small increase 
compared to increases of seven-fold or more in ALA synthetase activity 
of liver from patients with hepatic porphyria. However, the highest 
activity observed in an individual porphyric cat was almost five 
times the nonporphyric mean and almost three times the highest 
nonporphyric value. The observation that the mean ALA synthetase 
activity level found in the anemic nonporphyric cats approximated 
the mean level of the porphyric cats might suggest that the increased 
enzyme activity in porphyric cats was due to bone marrow stimulation 
78 
by erythropoietin; however, there was no direct correlation between 
the activity of ALA synthetase and the degree of anemia in the porphyric 
cats. In fact, the porphyric cat with the greatest bone marrow activity 
of ALA synthetase was not .anemic. '.Qle results of the ALA synthetase· 
studies in these investigations suggest that overactivity of this enzyme 
may be responsible for the biochemical abnormalities observed in feline 
porphyria; but,-,the small numbers of animals involved in these studies 
and the relatively low magnitude of increase do not provide conclusive 
evidence for overactivity of this enzyme as being responsible for the 
porphyric condition in the cat, 
The assay techniques used in these investigations for measurement 
of bone marrow enzyme activity have been accepted·by other workers but 
the heterogeneous population of cell types in the marrow may have con-
tributed to experimental error in that differences of low magnitude 
between the experimental groups are masked. This, coupled with the 
apparent mildness of the porphyric.conditiQn in affected cats, may ex~ 
plain why more pronounced differences .in ALA synthetase activity were 
not found between porphyric and nonporphyric animals. If satisfactory 
methods could be devised for obtaining a more homogeneous population 
of erythroid cells, especially cells of a similar age group, the assay 
procedures would provide a more standard basis for comparing data be-
tween porphyric and nonporphyric animals and might more clearly resolve 
differences that may be present. 
It is possible that the porphyric condition in the cats is 
secondary.to-a genetically determined metabolic abnormality outside the 
heme synthesis pathway, i.e., steroid influence on porphyrin metabolism 
(75,98). Also, ALA has been shown to participate in the biosynthesis 
of compounds other than those involved in heme biosynth~sis (135,124). 
A metabolic defect causing a decreased utilization of ALA by such 
pathways would channel more ALA-into heme biosynthesis, thereby accele"" 
rating the formation of .. PBG --and porphyrins if substantial amounts of 
ALA are normally used in.pathways other than heme biosynthesis. 
The results of the various studies reported in this thesis have 
failed to define the site or the specific nature of the metabolic defect 
responsible for feline porphyria; however, considerable information has 




The investigations were designed to more completely characterize 
the metabolic defect(s) involved in feline porphyria. The studies 
were divided into two phases. Phase I consisted of quantitation and 
characterization of urinary poX'phyrins and porphyrin precursors and 
of erythrocyte porphyrins in feline porphyria. Phase II consisted of 
measuring the comparative catalytic activities of three enzymes, ALA 
synthetase, ALA dehydrase and ferrochelatase, involved in the heme 
biosynthesis pathway in various tissues including liver, blood and· 
bone marX'OW from porphyric and nonporphyric cats. 
Results of the porphyrin and porphyrin precursor studies in por-
phyric cats showedt 1) markedly elevated urinary levels of uroporphy-
rin, coproporphyrin and porphobilinogen, 2) normal urinary levels of 
o-aminolevulinic acid, 3) markedly elevated levels of protoporphyrin 
and coproporphyrin and moderate elevations of uroporphyrin in erythro-
cytes, and 4) a predo~inance of the type I isomer of coproporphyrin 
in urine and erythrocytes. These biochemical findings indicate that 
feline porphyria is an unique type of porphyria having features both 
I 
of the ·erythropoietic and hepatic·porphyrias of man. Similarities to 
erythropoietic porphyria include elevations in erythrocyte prophyrins 
and the predominance of the type I porphyrin isomer; however, eleva-
tions of urinary porphobilinogen have been previously observed only 
RO 
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in hepatic porphyrias. 
Results of the enzyme studies in porphyric cats showed: 1) normal 
hepatic ALA synthetase and ALA dehydrase activities, 2) elevated 
erythrocyte ALA dehydrase activity, 3) normal bone marrow ferrochela-
tase activity, 4) slightly increased marrow ALA dehydrase activity, 
and 5) elevated marrow ALA synthetase activity. Mean activities of the 
three enzymes in marrow from five anemic nonporphyric cats were similar 
to the mean enzyme activities found in the porphyric group; however, 
marrow ALA synthetase was much higher in some porphyric cals than the 
highest values observed in the anemic group. 
The normal levels of ALA synthetase and ALA dehydrase in the 
hepatic tissue of porphyric cats suggest that the liver is not involved 
in excessive porphyrin and porphyrin precursor production. Elevation 
of erythrocyte ALA dehydrase activity was interpreted as a reflection of 
the reticulocytosis caused by the mild anemia in several of the por-
phyric cats. Results of the bone marrow enzyme studies suggest that 
ALA dehydrase and f errochelatase are not sites of defective heme bio-
synthesis in feline porphyria. 
The elevated ALA synthetase activity in bone marrow of porphyric 
cats provides an explanation for the excessive production of porpho-
bilinogen and porphyrins; however, anemic nonporphyric cats also had 
similar increases in bone marrow activity. Since many of the por-
phyric cats were mildly anemic, the importance of elevated marrow 
ALA synthetase activity in the pathogenesis of feline porphyria re-
mains to be clarified. 
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APPENDIX 
TABLE XIII 
HEMATOLOGIC DATA OF ANIMALS USED IN ENZYME 
STUDIES OF BLOOD AND BONE MARROW 
CAT Hb (gm%) PCV % Retie 
Pori,~hyric 
82 (grade 3) 11.4 35.5 1.8 
21 (grade 2) 12.6 38.0 Less 1.0 
213 (grade 3) 9.1 29.0 Less 1.0 
392 (grade 3) 12.0 39.0 2.6 
102 (grade 2) 8.7 27.0 4.8 
471 (grade 2) 10.8 33.5 1.8 
744 (grade 2) 9.3 27.5 2.0 
392 (grade 2) 12.1 35.5 l,. 4 
743 (grade 2) 11.9 34.5 1.6 
142 (grade 1 11.5 36.5 1.2 
141 (grade 1) 11. 9 34.0 1.4 
14 (grade 3) 9.8 30.5 1.0 
761 (grade 3) 11.6 35.0 1.0 
213 (grade 3) 9.4 27.5 
763 (grade 3) 9.5 29.5 3.0 
65 (grade 1) 11.5 34.0 
713 (grade 2) 15.3 45.0 Less 1.0 
102 (grade 2) 9.5 27.5 1.6 
Nonanemic Non2or2hiric 
6 14.1 44.0 1.4 
8 11.5 35.0 Less 1.0 
20 10.9 34.0 Less 1.0 
9 14.4 46.0 Less 1.0 
80 10.6 37.0 Less 1.0 
7 12.3 37.0 Less 1.0 
J-9 13.0 38.5 
J-1 11.9 35.0 
J-3 11.4 32.5 
J-4 12.4 37.5 
J-5 10.l 31.5 
J-8 10.6 31.0 
J-10 12.5 36.5 
J-11 13.3 38.0 
J-12 12.5 41.0 
J-13 12.2 35.5 
M-4 12.0 37.0 
M-5 13.6 41.0 
M-11 12.9 38.0 
M-12 11. 7 34.0 































TABLE XIII (c·c:i.ntinued) 
CAT Hb (gm%) PCV % Retie % Erythroid 
Nonanemic NonEorEhxric 
M-6 .13.4 40.0 12 
M-7 10.6 28.5 20 
M-10 16.2 45.5 14 
M-1 11.0 34.5 11 
M-15 15.9 46.5 23 
AnemicNonEOrEhxric 
M-2 9.1 31.0 14 
M-8 9.9 27.5 20 
K-1 9.3 27.5 Less 1.0 27 
K-2 10.5 32.0 Less 1.0 39 
K-3 9.1 25.0 Less 1.0 29 
TABLE XIV 
DAILY URINARY LEVELS OF PORPHYRINS AND PORPHYRIN 
PRECURSORS OVER A FOUR DAY PERIOD 
CAT micrograms/24 hour 
Porphyric ALA PBG URO CO PRO -
52 (grade 3) 331 514 178 43 
217 353 82 34 
540 496 109 44 
535 666 81 52 
82 (grade 3) 289 710 302 40 
86 328 94 35 
225 864 178 53 
202 508 156 36 
1 (grade 4) 480 2128 626 121 
275 1189 270 80 
233 1732 345 72 
77 226 80 15 
14 (grade 3) 481 570 257 83 
476 1067 363 98 
242 878 298 82 
360 1066 469 124 
11 (grade 2) 190 458 105 25 
210 389 90 25 
232 102 88 21 
























TABLE XIV (continued) 
CAT micrograms/24 hour 
Nonporphyric ALA ~ URO COP RO ml Urine 
5 170 209 9 5 31 
128 52 7 6 23 
22 7 2 18 8 
91 41 1 4 18 
80 36 0 3 3 178 
441 318 9 14 96 
340 76 9 8 20 
316 35 9 6 77 
70 1417 353 23 23 130 
806 0 8 6 58 
108 0 3 1 23 
1741 505 12 7 66 
6 385 249 12 8 110 
170 169 6 5 50 
360 181 7 9 100 
160 80 4 5 44 
7 71 237 7 6 35 
178 531 14 15 69 
50 69 3 4 16 
211 131 14 16 65 
TABLE XV 
HEPATIC ALA DEHYDRASE ACTIVITY 
CATS 
Porphyric 
522 (grade 1) 
523 (grade 1) 
521 (grade 2) 
182 (grade 1) 





















HEPATIC ALA SYNTHETASE ACTIVITY 
C.AT 
Porphyric 
101 (grade 2) 
653 (grade 1) 


























BONE MARROW ALA SYNTHETASE ACTIVITY 
CAT .I pmoles AL~/30 min. 
106 Erythroid Cells 106 Nucleated Cells . Mg."Prbtein ,. 
Porphyric 
65 (grade 1) 32 7.4 893 
141 (grade 1) 82 16.4 
142 (grade 1) 66 17.8 
713 (grade 2) 139 20.8 1762 
743 (grade 2) 173 17.3 1561 
342 (grade 2) 80 20.8 
744 (grade 2) 34 9.5 940 
102 (grade 2) 56 11.2 1347 
761 (grade 3) 103 13.4 
14 (grade 3) 47 10.8 783 
763 (grade 3) 45 13.0 1425 
213 (grade 3) 24 6.2 917 
Nonporphyric 
M-1 19 2.1 
M-4 23 5.3 
M-5 28 8.4 
M-6 74 8.9 
M-12 45 10.4 
J-1 32 7.0 601 
J-4 22 3.7 649 
J-5 15 1.8 
J-9 49 6.9 945 
J-10 . 15 3.2 576 
J-11 39 3.9 
J-12 56 9.5 1537 
J-13 77 13.1 2183 
M-7 52 10.0 
TABLE XVIII 
BONE MARROW ALA DEHYDRASE ACTIVITY 
.2.moles PBG/hour 
CAT 
106 Erythroid Cells 10 6 Nucleated Cells 
Porphyric 
141 (grade 1) 
142 (grade 1) 
342 (grade 2) 
743 (grade 2) 
744 (grade 2) 
14 (grade 3) 
















































BONE MARROW MITOCHONDRIA FERROCHELATASE ACTIVITY 
pmoles Heme/10 minutes CAT 
106 Erythroid Cells 106 Nucleated Cells 
Porphyric 
141 (grade 1) 
142 (grade 1) 
342 (grade 2) 
743 (grade 2) 
744 (grade 2) 
14 (grade 3) 


















































BONE MARROW HEMOLYSATE FERROCHELATASE ACTIVITY 
CAT 
Porphyric 
65 (grade 1) 
713 (grade 2) 
102 (gra~e 2) 
213 (grade 3) 
















pmoles Heme/10 minutes 
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